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Summary 
 
Post-translational modification of a large number of intracellular proteins with a 
single O-linked GlcNAc sugar is involved in various cellular processes. The 
dynamic nature of this O-GlcNAc modification has demonstrated its relevance in 
cell signalling and transcription regulations. At the centre of this complex 
regulatory network are two enzymes with antagonistic action: O-GlcNAc 
transferase (OGT) that catalyses the transfer of GlcNAc onto Ser/Thr side chains 
of proteins and O-GlcNAcase that removes the O-GlcNAc.  
The work in this thesis was focused on the O-GlcNAc transferase, using a 
combination of structural biology and cell biology approaches. OGT exhibits two 
defined domains, the N-terminal domain consisting of tetratricopeptide repeats 
(TPRs) and the C-terminal glycosyltransferase domain. The first chapter focuses 
on the functions of the TPR domain of OGT in substrate recognition. It also 
provides examples of how the TPR domain may affect the substrates through 
binding to TPRs. During the study using systematic TPR truncations, multiple 
expression constructs were generated and used for the production of stable and 
pure hOGT proteins, which led to a detailed study of the catalytic mechanism of 
hOGT with the aid of structural biology, as described in Chapter II. A novel 
glycosyltransferase catalytic mechanism is suggested for hOGT. Structural 
information gained from this thesis and other previous reports was employed to 
design further experiments using Drosophila model, aimed at investigating the 
involvement of OGT and O-GlcNAcylation during development, as described in 
Chapter III.    
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1.1. Glycosylation  
Oligo- and polysaccharides, or glycans, are the most abundant biomolecules on 
earth. In the linear or branched arrangement consisting of either mono- or 
heteropolymers of monosaccharide, glycans provide large diversity in live 
systems. Glycans can be secreted or attached to proteins or lipids, forming 
glycoconjugates. In human, more than 50% of proteins are glycoproteins through 
co- or post-translational modification (Apweiler et al, 1999). The attachment of 
glycans on a glycoproteins fall mainly into two classes depending on the glycol-
peptide linkage: attachment of sugar(s) to the nitrogen atom of asparagine (N-
glycosylation), and to an oxygen atom (O-glycosylation) predominantly to serine 
or threonines, although atypically on tyrosine, hydroxylproline and hydroxylysine 
have also been observed (Spiro, 2002).  
 
1.2. Historical overview of 
protein O-GlcNAcylation 
The post-translational modification of 
intracellular proteins with the 
monosaccharide β-D-N-acetyl-
glucosamine (GlcNAc) on serine or 
threonine was discovered in the 
1980s, while studying the composition 
of the terminal N-acetylglucosamine 
residues on the surface glycans of live 
Figure 1.1: Chemical structure of O-GlcNAc 
modified serine with both phosphorylation 
and O-GlcNAcylation. Both molecules are 
shown in balls and sticks representation. 
GlcNAc-Serine Phospho-Serine 
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lymphocytes (Torres & Hart, 1984) (Fig. 1.1). The authors probed for terminal 
GlcNAc moieties with radiolabeled UDP-GalNAc and bovine milk 
Galactosyltransferase (GalT1). It was found that O-GlcNAcylation is particularly 
enriched in the nuclei, especially on the nuclear envelope, and the soluble 
fraction in the rat liver tissue (Holt & Hart, 1986). Its localisation and non-
extending monosaccharide modification therefore differ from the classic cell 
surface glycan. Early studies have shown that the turnover of O-GlcNAcylation is 
faster than the protein that carries it (Chou et al, 1992; Roquemore et al, 1992); 
this dynamic feature of O-GlcNAc modification suggested its function in protein 
regulation. Over the years, with technical advances in O-GlcNAc detection, more 
than a thousand proteins have been found to be O-GlcNAc modified; and despite 
early speculation of targeting the carriers to the nuclei (Schindler et al, 1987),  
which are now believed to be involved in various cellular functions, as discussed 
later (Fig. 1.2).  
 
1.2.1. Phylogeny of O-GlcNAc Modification 
Post-translational modification on intracellular proteins by O-GlcNAc is highly 
conserved across species from bacteria to human. In the bacterium Listeria 
monocytogenes, flagellar protein FlaA was found to be modified with O-GlcNAc 
(Schirm et al, 2004; Shen et al, 2006). Although there is no clear evidence for the 
function of this modification, other O-linked glycosylation on flagellins have been 
shown to affect the assembly and motility of the flagella (Schirm et al, 2003; 
Thibault et al, 2001). In eukaryotes, O-GlcNAcylation has been found in 
organisms from the most ancient and primitive protist Giardia (Banerjee et al, 
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2009), to plants and animals from the most primitive multicellular placozoon 
Trichoplax adhaerens (unpublished) to higher animals like C. elegans, 
Drosophila, Xenopus, zebrafish, mouse and in human (Olszewski et al, 2010). O-
GlcNAcylation has not been reported in yeast to date.  
 
1.2.2. O-GlcNAc is Dynamic and Inducible 
Two enzymes carry out O-GlcNAc modification, O-GlcNAc transferase (OGT) 
adding GlcNAc moiety and O-GlcNAcase (OGA) removing it. The high-energy 
donor substrate of OGT is UDP-GlcNAc, an end product of the hexosamine 
biosynthetic pathway (Fig. 1.3). 2-5% of the total glucose consumption is 
converted into UDP-GlcNAc (Marshall et al, 1991b; Marshall et al, 2004). Many 
components in the hexosamine biosynthetic pathway, such as acetyl-CoA, 
24%!
15%!
10%!8%!
7%!
5%!
3%!
3%!
3%!
3%!
3%!
2%!
2%! 1%!
1%!
10%!
Signal Transduction!
Metabolism!
Cytoskeleton Remodeling!
Immune Response!
Cell Adhesion!
Neurophysiology!
Transcription!
Translation!
Cell Cycle!
Transport!
Muscle Contraction!
Chemotacis!
Apoptosis!
Figure 1.2: A pie chart representation of the intracellular proteins that have been found 
to be O-GlcNAc modified and their involvement in cellular processes.  
Percentage was calculated from the total number of the proteins carrying O-GlcNAcylation. Fig 
is adopted from Ruan et al., 2012, Cell Metabolism.  
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glutamine and UTP, are also involved in other metabolic pathways and play key 
roles. The synthesis of UDP-GlcNAc is therefore affected by the cross talk 
between different biosynthetic pathways and is subject to tight regulation. OGT 
activity is dependent on and regulated by the availability of the donor substrate 
UDP-GlcNAc. Fluctuation of the intracellular UDP-GlcNAc pool alters the global 
O-GlcNAc level through OGT. The cellular O-GlcNAc level can also be acutely 
elevated by the addition of glucosamine, bypassing the rate limiting enzyme in 
the hexosamine biosynthetic pathway, glutamine:fructose-6-phosphate 
aminotransferase (Marshall et al, 1991a) (Fig. I.3).   
 
It also appears that cellular O-GlcNAc levels are responsive to insulin, growth 
hormones and cellular stresses, including UV exposure, ethanol, heavy metals, 
heat shock, osmotic and oxidative stresses (Zachara et al, 2004). Pathologically, 
ischemia (Champattanachai et al, 2007; Zou et al, 2007), hypoxia (Ngoh et al., 
2009) and arterial injury (Xing et al, 2008) also induces O-GlcNAc flux.  
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Figure 1.3: Schematic overview of hexosamine biosynthetic pathway (HBP). Glucose 
is used in the HBP to produce UDP-GlcNAc as the final product. Glucose, as the upstream 
source of the hexosamine biosynthetic pathway, not only provides the scaffold but also 
contributes to the synthesis of many components for UDP-GlcNAc synthesis. The origin of 
each component is colour coded. Arrows indicate the direction of the pathway and 
enzymatic processes. Key enzymes are labelled next to the reaction (magenta). The figure 
is adapted from Banerjee et al., 2013, Chem. Soc. Rev. 
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1.3. O-GlcNAc Cycling Enzymes 
In cells, O-GlcNAcylation and its turnover is orchestrated by the antagonising 
actions of two enzymes, O-GlcNAc transferase (OGT) and O-GlcNAc hydrolase 
(OGA). 
 
1.3.1. O-GlcNAc Transferase (OGT) 
O-GlcNAc transferase, the enzyme responsible for the post-translational 
modification with O-GlcNAc, was affinity-purified using a synthetic substrate 
peptide from rabbit raticulocytes 8 years after O-GlcNAcylation was discovered 
(Haltiwanger et al, 1990). OGT was later purified from rat liver using an UDP-
hexanolamine-sepharose column (Haltiwanger et al, 1992). A 340 kDa protein 
complex was identified, which consisted of two 110 kDa and one 78 kDa 
subunits. These are two of three isoforms known today as nucleocytoplasmic 
OGT (ncOGT) and short OGT (sOGT). The authors observed at the time that the 
mitochondrial fraction contained 15% of the OGT activity (Hart et al, 2011; Love 
	  
TPR Catalytic Domain 
466 810 698 1036 1 	   13.5 TPRs 	   	   	  GT1 InD GT2 
	  	   8.5 TPRs MSS 	   	   	  GT1 InD GT2 
	  2.5 TPRs 	   	   	  GT1 InD GT2 	  
ncOGT 
mOGT 
sOGT 
Figure 1.4: Schematic representation of the domain structure of human O-GlcNAc 
transferase. Three isoforms OGT have been identified: nucleoplasmic OGT (ncOGT), 
mitochondrial OGT (mOGT) and small OGT (sOGT). All three OGT isoforms contain different 
length of tetratricopeptide repeats (TPRs) at the N-terminus (gray), except mOGT that starts with 
a mitochondrial specific sequence (MSS, slate). The catalytic domains of the three OGT 
isoforms are identical, with a glycosyltransferase domain of two lobe (GT1, red and GT2, blue) 
and a intervening domain (InD, green).  
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et al, 2003). Subsequently, an OGT isoform specific to mitochondria was 
reported and denoted as the mitochondrial specific OGT (mOGT) (Love et al, 
2003). The identification of the ogt gene demonstrated that all three isoforms are 
encoded from a single gene as the products of splicing (Shafi et al, 2000). They 
share an identical C-terminal glycosyltransferase domain and differ in the 
number of repeats in the Tetratricopeptide repeat (TPR) domain at the N-
terminus (Fig. 1.4). An additional mitochondrial targeting sequence in mOGT 
directs the protein to the mitochondria (Lubas & Hanover, 2000). ogt genes from 
many organisms have been cloned, including Arabidopsis thaliana (Hartweck et 
al, 2002), C. elegans (Hanover et al, 2005), Drosophila melanogaster (Gambetta 
et al, 2009; Sinclair et al, 2009), Xenopus laevis (Kenwrick et al, 2004), zebrafish 
(Webster et al, 2009), mouse (Shafi et al, 2000), and human (Lubas & Hanover, 
2000) . Sequence conservation is high throughout the catalytic domain as well as 
the N-terminal TPR repeats of metazoan OGTs, with the intervening domain 
being the least well conserved region of the protein (Fig 1.5). This intervening 
domain is absent in OGTs from bacteria such as Xanthomonas campestris and 
Listeria monocytogenes, the domain arrangement is, however, conserved. 
Uniquely, the catalytic domain of this Listeria monocytogenes OGT belongs to a 
different family of glycosyltransferases (GT2). (See later in General Classification 
of Glycosyltransferases) 
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Figure 1.5: Sequence conservation among metazoan O-GlcNAc transferases: 
Multiple sequence alignment of sequences of O-GlcNAc transferases from 
Xanthomonas campestris (UniProt: Q8PC69), Caenorhabditis elegans (O18158), 
Drosophila melanogaster (Q7KJA9), Xenopus laevis (Q641I4), Mus musculus 
(Q8CGY8) and Homo sapiens (O15294). Blue colour shades indicate the conservation 
across species.  
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1.3.1.1. O-GlcNAc Transferase is Involved in Many Cellular Processes  
 
Metazoan Embryogenesis 
Nearly all animals analysed appear to have a single ogt gene, except for 
zebrafish, which has two (Sohn & Do, 2005). Studies have shown that ogt is 
essential for the development in several animal models. In mouse, it has shown 
that the intact OGT gene is essential for the viability of ES cell and no mice with 
OGT deletion allele was produced with homologous recombination (Shafi et al, 
2000); nevertheless, the authors were able to generate mice with allele 
containing functional lox-P flunking Ogt gene, which would allow conditional 
knock out with Cre-lox system. By applying this conditional mutagenesis strategy, 
O’Donnel et al. was able to introduce OGT deletions in specific tissues with 
tissue specific promoter driving the expression of Cre recombinase, which 
mediates recombination event at the lox-P site and excises the target gene, in 
this case, Ogt gene (O'Donnell et al, 2004). T-cell specific knockout of OGT has 
been found to induce T-cell apoptosis by up to 75% within lymph nodes and 
spleen prior to emigration into peripheral. In neuronal specific ogt knockout mice, 
only half carrying deletion allele survived postnatal, but they fail to nurse and die 
within 10 days. It is also found increased Tau protein levels in the brain and 
spinal cord; Tau is also found hyperphosphorylated, which is often found 
associated with early death and neuronal apoptosis, and neurofibrillary tangle 
formation by hyperphosphorylated Tau is pathological hallmark of 
neurodegenerative disease Tauopathies (Brich et al, 2003; Kobayashi et al, 
2003). Fibroblast ogt knockout using retrovirus appeared senesce and die by day 
12; biochemical studies has shown that the cells were defective in serum 
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responses and decrease protein stability on transcription factors Sp1, c-Jun, c-
Fos and c-Myc in the absence of OGT and O-GlcNAc. In agreement, protein 
levels of transcription factor Tet1 is also reduced with depletion of OGT or 
replacing with an inactive mutant of OGT (Shi et al, 2013)., suggesting O-
GlcNAcylation might be important in transcription as discussed later in section 
1.7.1 Roles in transcription. Interestingly, many of the phonotypes were observed 
in cells undergoes cell division or during development, suggesting OGT and O-
GlcNAcylation primarily function in cell division as discussed in section 1.7.2 
Rose in cell cycle and cell division; aberrant levels of OGT or subsequence O-
GlcNAc levels would disrupt cell cycle program and lead to apoptosis. Recently, a 
report showed tissue specific OGT ablation in adult mouse heart did not lead to 
heart dysfunction (Watson et al, 2010), further support this hypothesis. 
 
The functions of OGT in neuronal development were also observed in zebrafish. 
In zebrafish, two ogt genes encode 6 variants. Var1, 2 express in the very early 
stages while var 3, 4 appear later, after the dome stage. Var5, 6 express 
throughout the development (Sohn & Do, 2005). OGT is expressed dominantly in 
the brain at 24 hours post-fertilization (hpf) and becomes more restricted at 36 
hpf and 72 hpf (Webster et al, 2009). Depletion of OGT levels by injecting 
morpholinos against each of the transcripts in the 1-4 cell stage led to increased 
cell death and developmental defects, producing embryos with shortened body 
axis, smaller brain and abnormalities in or absence of eyes. Necrotic tissue in the 
brain was also observed in these embryos. OGT depletions also caused modest 
change in global O-GlcNAc levels (Webster et al, 2009).  
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The outcome is not surprising given that O-GlcNAc modification has been found 
to be most abundantly in the brain (Dias & Hart, 2007). Recently, a study 
monitoring OGT expression and global O-GlcNAc levels in the rat brain over a 
two-year period has been reported (Liu et al, 2012). High levels of O-
GlcNAcylation was observed in the early development, followed by a marked 
decline in O-GlcNAc levels. The total OGT protein levels remain stable with 
alteration of the isoforms. OGT protein expression in early development has been 
studied before that. In Xenopus tropicalis, ogt RNA is found at low level 
throughout neurula embryos with high level at the anterior neural tube (Gawantka 
et al, 1998; Kenwrick et al, 2004). The ogt gene is later primarily expressed in the 
head at the tadpole stage. ogt depletion by morpholino injection produced 
embryos with gastrulation defects presenting as bifurcated axis (spina bifida), 
while the rest were truncated at the posterior end with little or no tail buds. These 
dramatic morphological defects observed in mouse, zebrafish and frog, produced 
by OGT depletion either with gene removal or morpholino depletion, suggest that 
the development, especially the neuronal development, in vertebrate, is sensitive 
to the change in OGT protein level, and possibly to fluctuations in O-GlcNAc 
levels.  
 
ogt in Drosophila is also known as super sex combs (sxc), which was first 
described in 1984 as a Polycomb group (PcG) gene that plays a repressive 
function on homeotic genes during the development. This suggests a function of 
OGT in transcription. Mutations of sxc led to homeotic transformation (Ingham, 
1984). Only recently, the product encoded by sxc was proven to be OGT and 
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mutations of sxc leading to OGT ablation also resulted in early death of the flies 
in pharate adults (Gambetta et al, 2009; Sinclair et al, 2009). The importance of 
sxc in the early embryogenesis is not clearly demonstrated in flies as the 
maternal transcripts and gene products in the oocyte can compensate for the 
lack of sxc on repression. Transgenic flies overexpressing sxc and hOGT were 
able to rescue this lethality (Sinclair et al, 2009), making Drosophila an excellent 
model for studying the functions of OGT and O-GlcNAcylation.  
 
Energy Sensing and Glucose metabolism 
Drosophila was also employed as a model system in the study of OGT and its 
involvement in energy metabolism. Genetically introducing raise in OGT protein 
levels in flies produces an increase in the body size and weight in larvae and 
adult (Sekine et al, 2010), which was also observed in the flies with reduced OGA 
protein levels, suggesting this effect may be caused by the elevation of global O-
GlcNAc levels. Conversely, reduction in OGT protein produces smaller larvae 
and adults. Drosophila insulin-like peptide (dilp) expression was also reduced in 
this OGT KD model, indicating the involvement of OGT and O-GlcNAcylation in 
glucose metabolism and insulin signalling.   
 
C. elegans with ogt null allele is viable and fertile, and phenotypically normal 
upon simple inspection (Hanover et al, 2005). The genomic rearrangement 
introduced an in-frame stop codon, producing a possible fragment of OGT with 
465 residues that retains the entire TPR repeat but without the catalytic domain. 
This ogt-1 mutant strain exhibited an abnormal energy homeostasis with 
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elevation in trehalose levels and glycogen stores, and a decrease in triglyceride 
levels; the OGT knockout also suppresses dauer larvae formation induced by a 
temperature-sensitive allele of the insulin-like receptor gene daf-2, also 
suggesting OGT has a function in energy sensing and the regulation of insulin 
signalling.  
 
The involvement of OGT in energy homeostasis is also observed in the plant 
Arabidopsis thaliana. There are two ogt genes, spindly (spy) and secret agent 
(sec) (Hartweck et al, 2002; Jacobsen & Olszewski, 1993; Silverstone et al, 
2007). Both are involved in plant growth hormone gibberellin signalling. OGT was 
shown to be essential: Single gene knock-outs produced mild effects, however, 
removal of both genes led to severe effects on germination, and embryos died 
before development (Hartweck et al, 2002).  
 
1.3.2. O-GlcNAcase (OGA) 
O-GlcNAcase was first identified as a cytosolic and neutral β-N-
acetylglucosaminidase and was called hexosaminidase C to distinguish from the 
lysosomal acidic hexosaminidase A and B (Braidman et al, 1974; Overdijk et al, 
1981; Swallow et al, 1976). OGA was first purified from rat spleen cytosol and 
later rat brain (Dong & Hart, 1994; Gao et al, 2001). Human OGA was cloned in 
2001 and was found to be identical to a previously identified gene, meningioma-
express antigen 5 (MGEA5), which was originally thought to be a hyaluronidase, 
since expression of these matrix-degrading enzymes is often associated with 
meningioma (Heckel et al, 1998). OGA is also highly conserved in eukaryotes, 
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and allows studying many model organisms, such as C. elegans, zebrafish, 
Drosophila and plant Arabidopsis (Olszewski et al, 2010). Northern blot has 
shown OGA transcript is expressed in all human tissue examined, with high 
levels in the brain, placenta and pancreas (Gao et al, 2001).  
 
There are two isoforms of OGA in eukaryotes (Fig. 1.6), with the shorter splice 
variant predominantly found in the nucleus of glioblastoma cells. The long splice 
variant contains an N-terminal hydrolase domain and a C-terminal histone acetyl 
transferase-like domain connected by a domain predicted to adopt mainly α-helix 
and a less conserved disordered region. This connecting region serves many 
biological functions; it is the site of caspase cleavage during apoptosis, 
phosphorylation (Wells et al, 2002; Whisenhunt et al, 2006). Most interestingly, 
the interaction of OGA and OGT occurs in the connecting region of OGA and 
allows the formation of a complex, or GlcNAczyme, that possesses antagonising 
action. The complex has been reported in repressor complex with Sin3A and at 
the midbody with phosphatase 1 and mitotic kinase Aurora B (Slawson et al, 
2008; Whisenhunt et al, 2006). The function of this OGT-OGA complex and how 
it is coordinated however is not clear understood. The HAT-like domain in OGA 
was shown to possess acetyltransferase activity on Lys8 of histone H4 and 
Lys14 of histone H3 (Toleman et al, 2004), but to date this finding has never 
been reproduced. Nevertheless, in addition to the catalytic domain, the HAT-like 
domain has been shown in yeast-two-hybrid experiments to contribute to protein-
protein interaction as observed in OGT (Butkinaree et al, 2008). The catalytic 
domain belongs to the GH84 glycoside hydrolase family and adopts the classic 
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TIM barrel fold demonstrated by the crystal structures of bacterial OGA 
homologues (Dennis et al, 2006; Rao et al, 2006). The structural information from 
these bacterial OGAs has provided invaluable insights and contributed to the 
development of many pharmacological inhibitors, that have been used to study 
the function of O-GlcNAcylation in vivo (Yuzwa et al, 2012). To date, the structure 
of hOGA is yet to be solved and the biological functions of O-GlcNAc 
modifications remain to be elucidated.   
 
 
  
Figure 1.6: Schematic representation of the domain structure of human O-GlcNAcase. 
Human O-GlcANcase consists of three distinctive domains: N-terminal glycosyl hydrolase 
domain (blue), C-terminal HAT-like domain (orange) and a middle domain, half of which has no 
predicted secondary structure. The short nuclear variant OGA (OGA-nv) lacks the HAT-like 
domain from the full length OGA (OGA-fl).  
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1.4. Effect of O-GlcNAcylation on Proteins 
1.4.1. O-GlcNAc modification induces conformational change  
The exact function of O-GlcNAc modification to the secondary structure of the 
target protein is not clearly understood. The modification leads to the addition of a 
large (comparing to O-phosphorylation) but uncharged moiety onto the substrate 
proteins (Fig. 1.1), which may presumably introduce local conformational 
changes, as occasionally observed for phosphorylation. Studies using 
biophysical methods, such as nuclear magnetic resonance and circular 
dichroism, have shown O-GlcNAc modification promotes turn-like structure 
formation on the C-terminal domain of PolII and the N-terminus of estrogen 
receptor β (Chen et al, 2006; Simanek et al, 1998). To date, no crystal structure 
of a protein carrying O-GlcNAc modification has been reported, partially because 
of the flexible nature of the modification site. The existing crystal structure of p53 
(DNA binding domain) may provide valuable information on the effect of O-
GlcNAc modification on protein architectures (Cho et al, 1994). Ser149 and 
Thr155 are found to be O-GlcNAcylated and phosphorylated, respectively (Yang 
et al, 2006). In crystal structures of the unmodified protein, both residues are 
located within a short ordered loop with the amino acid side chains buried. In 
order to be modified, significant rearrangement would be required, which may 
affect the nature of the protein. Another example is O-GlcNAc modification on 
histone 2B, where Ser112 is found an O-GlcNAc modification site (Fujiki et al, 
2011). Crystal structure of histone 2B containing Ser122 shows that this region, 
in the absence of any post-translational modification, adopts α-helical 
conformation (Luger et al, 1997). More interestingly, lys120, a previously reported 
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mono ubiquitination site, is also packed in the same helix (Fujiki et al, 2011). O-
GlcNAclyation on Ser112 induces conformational change and promotes K120 
monoubiquitination (Fujiki et al, 2011).  
 
1.4.2. Cross-talk between O-GlcNAcylation and phosphorylation 
Modulation of O-GlcNAc level in cells by changing OGT and OGA levels or 
pharmacological methods result in alteration of the cellular phosphoproteome, 
and vice versa (Slawson & Shaughnessy, 2005; Wang et al, 2008; Wang et al, 
2007), demonstrating the interplay between protein O-GlcNAcylation and O-
phosphorylation in cells. Since O-GlcNAcylation occurs on serine and threonine 
residues, competitive site occupancy is possible, and intracellular proteins may 
be reciprocally modified with protein phosphorylation at the same or adjacent 
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Figure 1.7: Schematic representation of the interplay between O-GlcNAcylation and O-
phosphorylation.  
Protein substrates are modified at serine or threonine residues. GlcNAcylation and 
phosphorylation mutually exclude each other at the same modification site. Enzymes 
performing the transfer reactions, OGT in O-GlcNAcylation and kinase in phosphorylation, are 
coloured in red; the enzymes performing hydrolysis, OGA and phosphatase (PPase), are in 
blue.   
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sites. Almost all the O-GlcNAc modified proteins identified so far are also 
phosphorylated, with some proteins showing a reciprocal relationship (Fig. 1.7) 
(Hart et al, 2011).  
 
Many reports have also demonstrated the involvement of O-GlcNAc modification 
in the regulation of protein stability, enzyme activity, cellular localisation and 
protein-protein interaction (Hart et al, 2007), however, in most cases the 
molecular mechanisms of these functions remain unclear. As yet, no O-GlcNAc 
binding protein or domain has been discovered.  
 
1.5. Roles of O-GlcNAc in Cellular Processes 
It is generally considered that O-GlcNAc has a close relationship with energy 
metabolism as mentioned in sections 1.4 O-GlcNAc is Dynamic and Inducible 
and 1.5.2.2. Energy Sensing and Glucose metabolism through UDP-GlcNAc in 
HBP. With the interlink with protein phosphorylation, O-GlcNAcylation provides a 
‘molecular switch’ that regulates many cellular processes. 
 
1.5.1. Roles in transcription 
Chromatin is enriched with O-GlcNAc modifications as shown by immunostaining 
of polytene chromosome in Drosophila, and later by chromatin 
immunoprecipitation; almost all of which are located at the transcription active 
regions (Gambetta et al, 2009; Kelly & Hart, 1989; Sinclair et al, 2009). Early 
Mass-spec studies have identified large group of proteins involving in protein 
transcription carry O-GlcNAc modification. One of the key component, the 
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catalytic subunit of the RNA polymerase II is found heavily O-GlcNAcylated at the 
C terminal tail, which contains a tandem of C-terminal repeat domains (CTD) with 
imperfect consensus sequence YSPTSPS (Dahmus, 1996). CTD is originally 
found to adopt either unphosphorylated or phosphorylated, and it has been 
understood that it serves to recruit other proteins during elongation (Phatnani & 
Greenleaf, 2006). Recently, Ranuncolo et al has suggested that O-GlcNAcylated 
RNA PolII at CTD represents the third status in addition to phosphorylated and 
unphosphorylated; the O-GlcNAc cycling on CTD is required for promoter activity 
(Ranuncolo et al, 2012) and O-GlcNAc needs to be removed prior to 
phosphorylation for elongation to occur as demonstrated previously (Comer & 
Hart, 1999). Many proteins involve in transcriptional regulation are also found to 
be heavily O-GlcNAcylated, including Sp1, c-Myc, Sin3A, p53, Tet1, Tet2, HCF1, 
CREB many of which also been found to directly interact with O-GlcNAc 
transferase (Chou et al, 1995a; Deplus et al, 2013; Goldberg et al, 2000; Hassig 
et al, 1997; Rexach et al, 2012; Vella et al, 2013; Williams et al, 2012; Yang et al, 
2006); and the roles involve in regulating their protein stability, cellular 
localisation, interactions with transcription complex. Histones, which regulate 
chromatin dynamic and gene expression, are also found O-GlcNAc modified 
(Fujiki et al, 2011).  
 
1.5.2. Roles in cell cycle and cell division 
Increasing numbers of evidence have supported the connections of O-
GlcNAcylation to cell cycle regulation and cell death. As mentioned previously, 
completely remove O-GlcNAcylation in mouse by OGT deletion causes 
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embryonic lethal (O'Donnell et al, 2004; Shafi et al, 2000); null mutations of both 
ogt genes, Spy and Sec, causes germination defect (Hartweck et al, 2002). In 
supporting this hypothesis, fibroblast growth arrest has been observed in mice 
with tissue specific ogt knockout (O'Donnell et al, 2004). Studies using Xenopus 
oocytes as model system have shown that microinjection with 
Galactosyltransferase that caps the O-GlcNAc inhibits aster formation during M-
phase (Fang & Miller, 2001). This observation was further supported with the 
microinjection of morpholinos against OGT into oocytes and found to delay M 
phase entry; microinjection of the ncOGT isoform that also increase O-GlcNAc 
levels produced opposite effect by potentiating M-phase entry (Dehennaut et al, 
2008). Later the same group has also shown that reduction of O-GlcNAcylation 
with OGT specific inhibitor slightly delay cell proliferation and they proposed that 
OGT activity is required for G1 to S transition (Olivier-Van Stichelen et al, 2012). 
With both genetic and pharcological method to reduce O-GlcNAc levels, it has 
shown that decreasing O-GlcNAc levels prevent cell division. However, similar 
results were also observed when increase O-GlcNAc levels. Reduction of O-
GlcNAc by microinjection of O-GlcNAcase inhibitor PUGNAc or inhibitor DON 
that prevent UDP-GlcNAc biosynthesis increases oocytes maturation time 
(Slawson et al, 2002). Similar experiments were also performed in mammalian 
cell lines by microinjection of PUGNAc into HeLa or 3T3-L1 cells and growth 
delay was also observed (Slawson et al, 2005). Despite of the contradictory 
results produced by manipulating O-GlcNAc levels, it is clear that cell division is 
under tight regulation and also involves O-GlcNAcylation. Microscopic study has 
shown that both OGT and OGA are presence at the midbody during mitosis and 
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complex with phosphatase 1 and mitotic kinase Aurora B. This observation 
suggests that there is an extensive cross talk between phosphorylation and O-
GlcNAcylation at midbody during cytokinesis (Slawson et al, 2008). Further study 
has identified more than hundreds of proteins that are involved in spindle 
assembly and cytokinesis (Wang et al, 2010).  Most importantly, many of the O-
GlcNAcylation sites are the same or adjacent to the phosphorylation site that 
involves in cytokinesis, supporting the role of O-GlcNAcylation during cell cycle 
event. In addition, intermediate filament vimentin is also a mitotic OGT substrate 
protein, whose O-GlcNAcylation was found increased after OGT overexpression 
and OGA inhibition; increase O-GlcNAcylation on vimentin decreases the 
phosphorylation that is crucial for vimentin rearrangement during mitosis, further 
support the involvement of O-GlcNAcylation in cell cycle regulation (Slawson et 
al, 2008). 
 
1.6. Chronic Diseases Involve O-GlcNAcylation 
Providing the potential involvement of O-GlcNAcylation in energy sensing, as well 
as a broad cellular activities of O-GlcNAcylated substrate proteins, it is not 
surprising that aberrant levels of O-GlcNAc in cells is often found to be 
associated with diseases.  
  
1.6.1. Type II diabetes 
Prolonged hyperglycaemia leads to insulin resistance, a hallmark of type II 
diabetes. High glucose levels increase the flux through the hexosamine 
biosynthetic pathway and increase global O-GlcNAc levels through the increase 
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of UDP-GlcNAc. Although malfunction of the hexosamine biosynthetic pathway 
has long been implicated in type II diabetes (Hart et al, 2011), the causality of 
elevated O-GlcNAc levels in the aetiology of the disease is unclear. The first 
direct link between global O-GlcNAcylation and type II diabetes came from 
studies using pharmacological inhibition of OGA activity, which resulted in a 
reduction of insulin-dependent glucose uptake (Park et al, 2005; Vosseller et al, 
2002). However, these studies used the non-specific hexosaminidase inhibitor 
PUGNAc. A more recently developed OGA specific inhibitor did not induce insulin 
resistance in 3T3-L1 adipocytes despite the increase of global O-GlcNAc levels 
(Macauley et al, 2008). Non-pharmacological methods of modulating O-GlcNAc 
levels also gave contradicting results. Reduction of O-GlcNAcylation by 
increasing OGA or reducing OGT protein levels in 3T3-L1 adipocytes did not 
prevent glucose-induced insulin resistance (Robinson et al, 2006). However, 
transgenic mice with adipocyte and cardiac muscle overexpression of hOGT lead 
to insulin resistance and hyperleptinemia (McClain et al, 2002). Studies in other 
animal models, such as in C. elegans and Drosophila, also support the direct 
involvement of global O-GlcNAcylation and insulin signalling (McClain et al, 
2002). Moreover, upon insulin stimulation OGT was found localized to the plasma 
membrane, where IRS proteins were O-GlcNAcylated (Yang et al, 2008). O-
GlcNAcylation of IRS prevents phosphorylation-dependent activation by insulin 
stimulation and interaction with PI3K p85 subunit. In the long term, alteration of 
global O-GlcNAcylation affects the activity of transcription factors, such as Sp1, 
and therefore their downstream gene expressions, aberrant levels of which have 
been found involving in diabetes (Love et al, 2010).   
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1.6.2. Neurodegenerative diseases 
The brain exhibits high level of OGT (Kreppel et al, 1997; Lubas et al, 1997). 
Many studies have reported the link between abnormal global O-GlcNAc levels 
and neurodegenerative diseases (ND). In a group of ND called tauopathies, the 
microtubule stabilising protein tau is found hyperphosphorylated and forming 
neurofibrillary tangles. These intracellular macroscopic aggregations are often 
found in brain tissue from patients with Alzheimer’s disease (AD), while in normal 
brain tissue, tau is hyper O-GlcNAcylated. This competitive site occupancy is 
believed to prevent hyper phosphorylation in healthy brain tissue (Arnold et al, 
1996; Lefebvre et al, 2010; Liu et al, 2004). Brain specific knock out of OGT 
protein in mice caused hyperphosphorylation of tau and abnormal locomotor 
activity (O'Donnell et al, 2004). Another pathology of the AD brain is neuronal 
plaques, which are caused by the aggregation of the degradation product of 
amyloid precursor proteins (APP). APP is found to be O-GlcNAcylated in the 
cytoplasmic domain and the modification may affect the cleavage of APP to form 
the toxic β-amyloid (Griffith et al, 1995). Many other proteins involved in brain 
functions are found to be O-GlcNAcylated, such as myriad synaptosomal proteins 
(Cole & Hart, 1999; Cole & Hart, 2001; Vosseller et al, 2006), AP-18, AP-3 (Yao 
& Coleman, 1998a; Yao & Coleman, 1998b), ataxin-10 (Marz et al, 2006), 
neurofilaments H, L and M (Dong et al, 1993; Dong et al, 1996). Although there is 
no direct report demonstrating the link of O-GlcNAcylation on those proteins to 
neurodegenerative disease, given the important roles of each protein plays in 
neuronal functions, O-GlcNAcylation on those proteins may serve functional 
purpose, especially with the interplay with phosphorylation.  
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1.6.3. Cancer 
Aberrant levels of global O-GlcNAcylation are also implicated in cancer. 
However, the roles of O-GlcNAcylation in cancer are less clear. Many proteins 
involved in cancer development are found to be O-GlcNAcylated, including c-Myc 
(Chou et al, 1995a; Chou et al, 1995b), Rb (Wells et al, 2011), p53 (Yang et al, 
2006), estrogen receptor β (Cheng & Hart, 2001). OGT is found localised at the 
midbody during mitosis, and overexpression leads to mitotic defects such as 
polyploidy, which is often associated with cancer (Slawson et al, 2005). On one 
hand, it has been shown that upregulation of OGT and O-GlcNAcylation have 
been found in certain types of breast cancer; reduced O-GlcNAcylation has been 
shown to inhibit tumour growth and metastasis in vivo (Ball et al, 2006). On the 
other hand, high O-GlcNAc levels may prevent tumour progression in chronic 
lymphocytic leukemic lymphocytes (Matthews et al, 2005). In this case, high O-
GlcNAc levels may play a protective role in cancer development as opposed to 
the cancer promoting functions. It is not clear how the O-GlcNAc levels affect 
cancer cells and its transformation. Possibly, the involvement of O-GlcNAcylation 
in cancer is depending on the cancer types and their pathology.  
 
1.6.4. Cardiovascular diseases 
Elevation of global O-GlcNAc level may also protect against acute cardiovascular 
diseases. It has been shown that acute hyperglycaemia-induced hyper-O-
GlcNAcylation improves the survival of heart tissue from ischemia and hypoxia 
(Champattanachai et al, 2008; Liu et al, 2007). Chronic hyper-O-GlcNAcylation 
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however causes cardiomyopathy as observed in diabetes (Hu et al, 2005; Liu et 
al, 2007). 
 
1.7. General Classification of Glycosyltransferases 
Glycosyltransferases (GT) catalyse glycosidic bond formation between activated 
high-energy glycosyl donors and a wide variety of acceptor substrates ranging 
from simple or complex carbohydrates to proteins, nucleic acid, lipids, antibiotics 
and other metabolites. Based on amino acid similarities, only 27 families of 
glycosyltransferases were documented in 1997 (Campbell et al, 1997; Coutinho 
et al, 2003). Over the past 15 years, studies have advanced our understanding of 
glycosyltransferases and allowed more accurate classification according to 
information such as the protein structure, substrate specificity, metal dependence 
and stereochemical outcome of the reaction (Haltiwanger et al, 1992). To date, 
there are 94 families of GTs documented in the CAZy database of carbohydrate-
active enzymes (http://www.cazy.org/GlycosylTransferases.html). Most 
importantly, glycosyl donors are the sugar nucleotides derivatives, which are 
utilised by large numbers of glycosyltransferases. The sugar nucleotide was first 
discovered by Luis F. Leloir (Caputto et al, 1950) and the enzymes that use them 
are often referred to as Leloir enzymes.  
 
1.7.1. Structural Insights into Glycosyl transfer 
Structural enzymology of glycosyltransferases is challenging for a variety of 
reasons, and this class of enzymes is therefore less well understood than others. 
Many glycosyltransferases are membrane-associated proteins, and a high 
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content of flexible regions in the proteins also makes crystallisation difficult to 
achieve. To date, crystal structures of only 137 glycosyltransferases in total have 
been deposited in the PDB database, most of which in the last 10 years. The 
structural information has further expanded our understanding of this class of 
enzyme and the enzymatic action of the glycosyltransferase begins to emerge.  
 
Despite the great diversities of the GTs, structural studies have revealed that all 
Leloir GTs adopt one of the two general folds, namely GT-A and GT-B folds, both 
of which contain two Rossmann-like folds, a β/α/β protein motif often found in 
nucleotide binding proteins and therefore allowing Leloir glycosyltransferase to 
bind to sugar nucleotide donor substrates (Fig. 1.8). 
  
The first structure of Leloir glycosyltransferase, a DNA-modifying β-
GT-A 
GT-A 
Figure 1.8: Cartoon representation of overall folds observed for glycosyltransferases. 
Cartoon representation of GT-A fold represented by SpsA from Bacillus subtilis (A; pdb: 
1QGQ) and GT-B fold by bacteriophage T4 β-glucosyltransferase (B; pdb: 1JG7). α-helices 
are in red, β-strands are in yellow and loops are in green. 
GT-B 
GT-A 
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glucosyltransferase from T4 bacterial phage (BGT), was reported in 1994 
(Vrielink et al, 1994). It reveals two less tightly associated Rossmann-like 
domains and a cleft in between, which was found later to harbour the active site 
(Lariviere & Morera, 2002). This overall arrangement of the Rossmann-like 
domains was observed for many other glycosyltransferases and denoted as GT-
B fold. The first GT-A fold glycosyltransferase, SpsA from Bacillus subtilis, was 
reported in 1999 (Charnock & Davies, 1999a; Charnock & Davies, 1999b). In 
contrast to the GT-B fold, the structure revealed two closely associated 
Rossmann folds forming a single domain with a continuous central β-sheet. Most 
GT-A glycosyltransferases are metal dependent enzymes and posses an Asp-X-
Asp (DXD) motif in which the negative charges of the carboxylates coordinate a 
divalent cation to interact with the phosphates of the nucleotide and facilitate the 
leaving group formation. This DXD motif is not often observed in the GT-B 
glycosyltransferases, which are generally metal-independent. The cation is 
replaced by positively charged amino acid side chains in the catalytic site. Non-
Leloir GTs may adopt the GT-C fold, which contains a hydrophobic domain and 
embedded in the membrane (Lizak et al, 2011), as well as a fold resembling 
bacteriophage-lysozyme (Lovering et al, 2007). 
  
1.7.2. Mechanism of Glycosyl Transfer 
Stereochemistry of the anomeric carbon in a sugar allows two different outcomes 
of the glycosidic bond formation; the product either inverts or retains the 
configuration with respect to the donor substrate. The enzymes that catalyse 
glycosyl transfer can therefore be classified as either retaining or inverting 
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glycosyltransferases, depending on the outcome of the reaction. 
Glycosyltransferases employ either inverting or retaining mechanisms have been 
reported to adopt both GT-A and GT-B folds (Fig. 1.9). 
The general principle of the 
inverting mechanism employed 
by glycosyltransferases is 
usually an SN2-like direct 
displacement reaction: a 
catalytic base, usually a side 
chain from an active site amino 
acid, deprotonates the incoming 
hydroxyl group of the acceptor 
substrate and activates it for 
nucleophilic attack onto the 
anomeric carbon (C1) of the 
sugar moiety. Concomitantly, a 
positively charged species 
stabilises the negative charge 
developing on the leaving group, thus facilitating the substitution at the anomeric 
carbon; a new covalent bond is in turn formed on the opposite side  (Fig. 1.10a). 
The catalytic base and the positive charges that stabilise the leaving groups are 
the key components of this process. Identification of this base, as well as the 
method to facilitate the leaving phosphate group, are essential in understanding 
an inverting glycosyltransferase.  
Figure 1.9: Schematic representation of general 
glycosyltransfer reaction and classification of GT 
families. The inversion or retention denoted on the 
anomeric stereochemistry with respect to the donor 
substrate (A). Both GT folds employ inverting or 
retaining mechanism (B). GT families belongs to each 
clan are indicated on the right. The sorting is based on 
predictions on the Cazy database and Liu et al., 2003. 
Families with solved structures are indicated in red. 
Asterisks mark the protein fold predicted by Liu et al., 
2003.  
A 
B 
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Figure 1.10: Schematic representations of reaction mechanisms of glycosyltransfer.  
Inverting glycosyltransfer (a) utilises a direct-displacement SN-2 like mechanism resulting in 
a product with inverting stereochemistry at the anomeric carbon. Two proposed retaining 
glycosyltransfer mechanisms with (b) an SN-2 like double displacement forming temporary 
covalent sugar-enzyme complex or an alternative (c) an SN-1 like dissociative mechamism 
by forming ion pair in the transation status. Noticeable that in the SN-1 like retaining 
mechanism, the donor and the acceptor are on the same side of the sugar plane compared 
to the opposite side in the inverting mechanism. Figure is adopted from Lairson et al., 2008, 
Annu. Rev. Biochem.   
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The aforementioned GT-A fold glycosyltransferase SpsA from B. subtilis belongs 
to an inverting glycosyltransferase family GT2. Despite the fact that both the 
donor and acceptor substrates are unknown, the crystal structure of SpsA was 
less informative, because a molecule of glycerol from the cryoprotectant was 
observed bound to the active site of SpsA, mimicking the acceptor substrate. The 
study led to the identification of an aspartic residue (Asp191) within hydrogen 
bonding distance to the glycerol, which was proposed to act as the catalytic base. 
Interestingly, in several structural studies, either Asp or Glu residues have been 
found at the equivalent position of the Asp191 in the active site of GT-A fold 
glycosyltransferases, within hydrogen bonding distance to the acceptors, 
confirming their involvement in the base catalysis (reviewed in Lairson et al., 
2008). Mutagenesis studies at the relevant position of Asp191 led to loss of 
enzyme activity and demonstrated the essential role of this residue in the 
glycosyltransfer reaction (Garinot-Schneider et al, 2000).  
 
The enzymatic base catalysis has likewise been reported in inverting GT-B 
glycosyltransferases. β-glycosyltranferase (BGT) from T4 bacteriophage was the 
first Leloir type glycosyltransferase using UDP-Glc as donor substrate (Vrielink et 
al, 1994). A conserved Asp100 was proposed to serve as the catalytic base 
based on structural and mutagenesis studies (Lariviere & Morera, 2002; Morera 
et al, 2001; Vrielink et al, 1994). The D100A mutation causes enzyme inactivation 
and enabled the crystallisation of a protein complex with the intact donor 
substrate (Lariviere et al, 2002). BGT is a metal-dependent inverting 
glycosyltransferase. However, the divalent ion serves no function in the 
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glycosidic bond cleavage but to facilitate product release. The metal ion was only 
found in the UDP complex, but not in the UDP-Glc complex, replacing the 
glucose. The negatively charged pyrophosphate group is found neutralised by the 
positively charged amino acid side chains in the active site and a helix dipole of 
the enzyme, instead of the metal ion. This arrangement is commonly found in 
many metal-independent inverting GT-B glycosyltransferases, such as GtfA, GtfB 
and GtfD (Mulichak et al, 2003; Mulichak et al, 2001; Webb et al, 2004). Proton 
extraction and activation of the acceptor could also be more indirect than the 
direct interaction with Asp or Glu side chains described earlier. Many 
glycosyltransferases of this class, such as UGT71G1 (Shao et al, 2005), VvGTI 
(Offen et al, 2006), OleD, OleI (Bolam et al, 2007), UGT2B7 (Miley et al, 2007), 
and bifunctional N/O-glycosyltranferase (Brazier-Hicks et al, 2007), are thought to 
utilize a catalytic dyad consisting of imidazole side chain of a histidine in 
conjunction with Asp or Glu.   
 
The mechanism of retaining glycosyl transfer is less clear than the inverting 
mechanism. In general, two controversial mechanisms have been proposed: a 
SN-2 like double-displacement with a covalent enzyme-substrate intermediate 
was originally proposed by Koshland (Koshland, 1953), and an alternative SN-1 
like oxocabenium ion intermediate has been proposed by Phillips (Phillips, 1966). 
In spite of extensive research, little evidence for such covalent intermediated 
exists, which makes the SN-i-like mechanism more likely. This mechanism 
dispenses with the need for acid-base catalysis and postulates a late transition 
state where the enzyme facilitates dissociation of the donor to such an extent that 
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the reaction constitutes electrophilic migration of the resulting oxocarbenium ion 
rather than a nucleophilic attack. In retaining GTs the acceptor approaches the 
sugar from the same side as the leaving group, consequently the product itself 
has been described as the proton acceptor by Aktories et al (Ziegler et al, 2008). 
 
1.8. Structural Insight into O-GlcNAc Transferase 
 
Based on sequence conservation, OGT was classified into the GT41 family, a 
group of inverting GlcNAc transferases adopting the GT-B fold. OGT was first 
purified from animal tissue, and demonstrated that metal ions are not required for 
its enzymatic activity (Haltiwanger et al, 1992). All members of the GT41 family 
are believed to transfer sugars directly onto protein substrates, and all members 
also contain TPR repeats.  
 
1.8.1. Structure of Tetratricopeptide repeats (TPRs) 
TPR is a structural motif of 34 amino acids adopting a helix-turn-helix fold. The 
sequence is characterized by conserved amino acids located at the interface of 
the two helices, at positions 8, 20 and 27 by small hydrophobic residues and at 
positions 4, 7, 11 and 24 by large hydrophobic residue; a proline residue is often 
found in the loop connecting the helices (Allan & Ratajczak, 2011; D'Andrea & 
4 
7 
1
1 
24  
8 
20 
27  
Pro 
Figure 1.11: Arrangement of TPR motif 
Cartoon representation of a single TPR motif 
from hOGT TPR 12. Large hydrophobic 
residues are shown by cyan sticks and the 
positions are numbered in red; while the 
small hydrophobic residues are shown in 
yellow sticks and numbered in blue. A 
proline is positioned at the turn shown by 
pink sticks. 
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Regan, 2003; Zeytuni et al, 2012) (Fig. 1.11 & Fig. 1.12). Mutations of these 
conserved residues disrupt the folding of the TPR (Jinek et al, 2004). Typically, 
TPR containing proteins consist of 3-16 copies of this motif, arranged in tandem 
array and forming a right-hand super-helical structure with a concave and a 
convex surface (Sikorski et al, 1990). Using bioinformatics techniques, more than 
5,000 TPR containing proteins have been identified in all organisms, from 
bacteria to human; many of these proteins are involved in multiprotein complexes 
(Allan & Ratajczak, 2011; D'Andrea & Regan, 2003; Zeytuni et al, 2012).  
 
The crystal structure of the major portion of the TPR from the long isoform of 
human ncOGT comprising 11.5 repeats was reported in 2004 (Jinek et al, 2004), 
providing structural and functional insight into substrate binding. Each of pair of 
antiparallel helices stacks with adjacent TPR units and the overall structure 
reveals a ‘corkscrew-like’ right-handed super spiral structure with a groove along 
the longitudinal axis (Fig. 1.13A). This topology shares great structural similarity 
Figure 1.12: Schematic representation of the conservation of 
concave surface residues in hOGT TPRs.  
Note the highly conserved Asp residues at the position 6 in each 
TPR. Conserved residues with charged side chains are marked in 
orange, other conserved residues are in pink. Residues forming 
interactions for dimerization are in brown. Essential amino acid 
residues for helix-turn-helix are listed in the consensus below each 
position. Figure is adopted from Jinek et al. 2006 Nat Struct Mol 
Biol 11: 1001-1007.  	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to the HEAT repeat from PP2α and the ARM repeat from importin-α (Conti & 
Kuriyan, 2000; Groves et al, 1999). Most conserved residues are restricted to the 
α-helices. More interestingly, highly conserved asparagine residues at the 6th 
position of each TPR repeat form a ladder along the concave surface (Fig. 1.12). 
This arrangement was also found in importin-α and shorter TPR-containing 
proteins Pex5, Hop, PP5 and Tom70 (Kikuchi et al, 2003; Ramasamy et al, 2005; 
Strahl-Bolsinger et al, 1993; Takahashi et al, 1996), in all of which the Asn 
ladders are found to interact with the backbone of a peptide that the TPR motifs 
bind (Fig. 1.13B). The authors also suggested substrate recognition might be at 
different sets of the concave surface and conserved Asn residues, analogously to 
importin-α, where different types of nuclear localisation signal are recognised by 
different sets of the conserved Asn residues, independent of the peptide 
sequence (Ramakrishnan et al, 2002; Ramakrishnan et al, 2006). The TPR 
domain of OGT also forms a dimer at TPR 6 and 7 through hydrophobic 
interaction. Mutations disrupt the interaction and reduce the enzyme activity by 
40% (Jinek et al, 2004). Three isoforms of OGT with different length of N-terminal 
TPR have been shown to recognise different sub-groups of substrates. This 
isoform-specific substrate recognition has been suggested as an evolutionary 
solution for the challenge that a single ogt gene is available to modify a large 
number of substrates involved in various functions in the cell (Lazarus et al, 
2006). 
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Figure I.13: Surface representation of the overall architecture of hOGT TPR domain in 
comparison with the ARM repeat from importin-α . The Asp residues at position 6 form a 
ladder along the concave surface of the superhelix (a, left). This arrangement has been found 
at the same position in the ARM repeat, in which the Asp residues are responsible for NLS 
peptide binding (a, right). Zoomed in view of Asp residues and interaction with NLS peptide 
(b). Figure is adopted from Jinek et al. 2006 Nat Struct Mol Biol 11: 1001-1007.    
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1.8.2. OGT Glycosyltransferase Domain 
The first crystal structures from family GT41 came from an OGT orthologue from 
the bacterial plant pathogen Xanthomonas campestris (Clarke et al, 2008; 
Martinez-Fleites et al, 2008). Although this bacterial protein lacks the intervening 
domain found in all metazoan OGTs, XcOGT shows 36% sequence identity to 
hOGT in the catalytic domain, and has three classic TPRs. The XcOGT 
structures confirmed that OGT adopts the GT-B fold. Demonstrated by several 
complexes with UDP and UDP-GlcNAc derivatives, the active site is located in 
the groove between the two Rossmann-like folds as in all GT-B fold 
glycosyltransferases (Fig. I.12b). The TPR at the N-terminus abuts on the 
catalytic domain and the superhelical groove of the TPR motif extends into the 
Figure 1.14: Cartoon representation of the XcOGT structure (left) and its catalytic site with 
UDP and its derivatives (right).  
Two lobes of the catalytic domain (blue and red) with closely associated TPR repeat (grey) 
forming a groove. UDP is deeply buried in the pocket, surrounded by a group of highly conserved 
residues (red). The uridine from UDP (pdb: 2VSN), UDP-C-GlcNAc (pdb: 2JLB), UDP-S-GlcNAc 
(pdb: 2XGO) and C-UDP (2XGS) are perfectly superimposed, while the phosphate and sugar 
moiety are less so.   
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active site, forming a continuous groove in which the substrate peptide may be 
recognised and bound. Unfortunately, the natural acceptor and donor substrates 
for XcOGT are not known. In 2011, the crystal structure of a truncated hOGT 
construct, bearing 4.5 TPRs and the catalytic domain, was solved by the Walker 
group (Lazarus et al, 2011). Most importantly, two structures of hOGT and UDP 
with or without acceptor peptide were reported. These complexes provided the 
first evidence of how OGT recognises the substrate at the peptide level, and 
demonstrated unambiguously through structural and kinetic studies that OGT 
uses an ordered bi-bi catalytic mechanism. As observed in the XcOGT structure, 
the active site groove is a narrow cleft between the TPRs and the catalytic 
domain in the OGT-UDP structure, however, this is widened slightly in the 
presence of the acceptor peptide. Although the two complexes were obtained 
from different crystallisation conditions, this suggests that the TPRs possess 
Figure 1.15: Cartoon representation of the hOGT catalytic domain with 4.5 TPR (left) and its 
catalytic site with UDP and a peptide from hOGT substrate CKII (right).  
Structure shows the architecture of catalytic domain (red and blue) with 4.5 TPR (grey) is similar to 
the XcOGT and the novel intervening domain (green) that is absent in XcOGT. Zoom in view at the 
catalytic site surface (pink) shows the binding of the CKII peptide (yellow) and its limited interaction 
with hOGT. CKII peptide covers the UDP-GlcNAc binding pocket, suggesting an ordered bi-bi 
catalytic mechanism. Amino acid residues interact with UDP (salmon) and create a pocket for 
GlcNAc binding. The position of the GlcNAc moiety (blue) is the result of a modelling experiment. 
Suggested catalytic bases His498 and His558 have been marked by red boxes.    
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plasticity and can change conformation to allow substrate binding. No OGT-UDP-
GlcNAc complex was obtained due to the hydrolysis, as the authors suggested.  
 
The metazoan-specific intervening domain that was absent in the XcOGT 
structure was reported to adopt a topologically novel fold containing a seven-
strand beta-sheet stabilised by flanking helices. This intervening domain also 
forms a large positively charged patch of ten lysine residues on the opposite 
surface from the catalytic groove. These lysine residues were previously 
suggested to be the PIP3 binding motif responsible for the hOGT membrane 
localisation upon insulin stimulation (Yang et al, 2008).  
 
Before the work from this thesis, the mechanistic action of OGT on O-GlcNAc 
transfer on substrate proteins was unclear. All the speculations were based on 
the crystal structure of the catalytic domain from bacterial ortholog XcOGT 
(Clarke et al. 2008; Martinez-Fleites et al., 2008). Also, a recent published crystal 
structure of hOGT catalytic domain (Lazarus et al., 2011). The new hOGT 
structure, however, lacks the GlcNAc moiety and clear data to support for the 
hypothesis of the catalytic mechanism, as well as the involvement of the TPR in 
the catalysis.  
 
In the following chapters, I have used a combination of structural biology together 
with the support of biochemical and biophysical to prove the hypothesis and 
demonstrated the unusual catalytic mechanism employed by hOGT. Later in the 
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chapters, a Drosophila system was employed to demonstrate the important of 
this catalytic activity for the survival and early development of flies.  
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2. Chapter I 
 
Functional Study of Tetratricopeptide Repeat 
Domain in Human O-GlcNAc Transferase 
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2.1. Project Overview 
O-GlcNAc transferase (OGT) post-translationally modifies intracellular 
proteins on Ser or Thr residues with a single GlcNAc moiety and has been 
shown to be essential for embryogenesis and early development in metazoa 
(Hart et al, 2011; Love et al, 2010). The protein is comprised of N-terminal 
tetratricopeptide repeats (TPRs) and the C-terminal glycosyltransferase 
domain. Three splice variants, with differing lengths of the N-terminal TPR 
domains, have been identified encoded by a single gene (Shafi et al, 2000). 
The longest isoform (ncOGT) contains 13.5 TPRs and the short isoform 
(sOGT) contains 2.5 TPRs, both these isoforms are uniformly localised in the 
cytoplasm and nucleus; while in the third isoform the first 5 TPRs are replaced 
by a mitochondrial specific sequence (MSS) containing 8.5 TPRs, and the 
protein is localised specifically in the mitochondria (mOGT).  
 
Where structural information is available, it indicates that the ligands binding 
to TPR domains frequently consist of flexible peptides, which may be found 
docked in the concave surface formed by the TPR superhelix (Quinaud et al, 
2007; Sampathkumar et al, 2008; Wang et al, 2009; Zeytuni et al, 2012). 
Although TPRs are highly conserved at the above-mentioned positions, the 
surface-exposed amino acids are less stringently conserved. In contrast to 
other similar helix domain containing proteins, such as 14-3-3 proteins 
(Coblitz et al, 2006), no consensus sequence has been identified among the 
ligands of TPR domains. However, individual TPR domains have been shown 
to exert some selectivity for the peptide sequence of the binding partner 
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(Sampathkumar et al, 2008; Zeytuni et al, 2012). However, flexible peptides 
are not the only type of ligand recognized by TPR domains, other methods of 
binding have been observed in several structural studies, where TPR motifs 
were found to bind α-helices at both the concave and convex surfaces, as 
well as proteins containing multiple TPR domains and dimerization mediated 
by the TPR (Jinek et al, 2004; Sampathkumar et al, 2008; Zhang et al, 2010).  
 
It has been proposed that interactions with the TPR domain of OGT enables it 
to act on a large variety of substrates, as well as providing isoform selectivity 
for specific substrates (Chen et al, 2013; Iyer & Hart, 2003; Lubas & Hanover, 
2000; Yang et al, 2002; Zhang et al, 2012b). The available crystal structure of 
the TPR domain of ncOGT contains 11.5 of the 13.5 repeats, revealing the 
canonical right-hand superhelical structure (Jinek et al, 2004). In this 
structure, groups of highly conserved polar or charged residues have been 
shown to cover the concave surface of the superhelix. Especially, recurrent 
arginine residues were noticed at position 6 on each TPR motif, forming a 
ladder that resembles the Asn-ladder observed in the armadillo repeats in 
importin-α (Conti & Kuriyan, 2000). The conserved concave surface and the 
Asn-ladder suggest that this surface may represent a binding interface for 
peptide ligands, which would bind along the axis of the TPR super-helix. 
Multiple peptides binding to one TPR domain has been demonstrated in 
peroxin 5 (PEX5), a cargo adaptor protein from Trypanosoma brucei. Pex5 
contains 7 TPRs, which are able to bind type 1 or type 2 peroxisomal 
targeting signal peptides; crystal structures of complexes of PEX5 and five 
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ligand peptides showed the TPRs clamping the peptides in position, all of 
which adopt similar conformations (Sampathkumar et al, 2008). In addition, 
adaptor protein Hop contains two individual TPR domains with selective 
binding affinity for Hop binding partners Hsp70 and Hsp90 (Scheufler et al, 
2000). These finding suggest that OGT substrates may bind in different 
positions on the OGT TPR domain, forming specific interactions with 
individual repeats.  
 
TPR participation in the recognition of individual substrates by OGT has been 
the subject of several independent studies (D'Andrea & Regan, 2003; Iyer & 
Hart, 2003; Love et al, 2010; Quinaud et al, 2007; Zhang et al, 2010). In this 
chapter, I describe the detailed study of the functions of the TPR domain of 
OGT by systematic removal of TPRs from the N-terminus, and by determining 
the effect of these truncations on O-GlcNAcylation of substrate proteins with 
different structural properties. I propose that substrate interactions with the 
TPR domain may induce conformational changes in the substrate, thereby 
giving access to the site of O-GlcNAcylation. This leads to the hypothesis of 
two OGT substrate-binding models: the TPR-independent recognition of loose 
peptides or flexible regions as opposed to a model of TPR-induced fit.    
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2.2. The aims of the work presented here were: 
• To identify an expression construct to produce proteins for future 
crystallization studies 
• To study the roles of the TPR domain in OGT substrate recognition by 
systematic TPR deletion 
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2.3. Results (Part1): 
2.3.1. Design of an OGT expression construct through systematic N-
terminal truncations lead to the stable and active ∆TPR hOGT 
Three splicing isoforms of human OGT have been reported, and the longest 
splice variant is found in both cytoplasm and nucleus (ncOGT) (Love et al, 
2003). The protein is 1046 amino acids in length with a calculated molecular 
weight of 117 kDa. ncOGT comprises of two principle domains, the N-terminal 
thirteen and a half tetratricopeptide repeats (TPRs) and the C-terminal 
glycosyltransferase (GT) domain. Mitochondrial OGT (mOGT) and short OGT 
(sOGT) are both shorter than ncOGT with 8.5 and 2.5 TPRs respectively, and 
with an identical C-terminal GT domain (Fig. 1.4). Previously, recombinant 
expression of the ncOGT was most successful using the insect cell sf9/sf21 
baculovirus system, while bacterial expression has been problematic and 
resulted in extremely low yield and purity. A model built on the basis of the 
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Figure 2.1: Expression and purification of hOGT (nc) TPR truncations in 
ArcticExpress cells. 	  
A: Total lysate of the E coli from 10 µl of the expression culture were boiled in 
sample buffer. Samples were separated on a SDS-PAGE and the gel was stained 
by Coomassie blue. 	  
B: hOGT proteins with TPR truncations were purified and the purity was assessed 
by SDS-PAGE. The gradual change in size was noticeable. ΔTPR1 is expressed 
but fail to be purified, suggesting the protein is unstable or insoluble. 	  
A	   B	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two structures available at the beginning of this project, namely the TPR 
domain from ncOGT and the bacterial homologue GT domain has shown that 
while the last repeat of the TPRs closely abuts on the GT domains, the 
remaining TPRs form a spiral extending away from the catalytic core. This 
was taken as indication that the removal of the TPRs from the N-terminus 
would have little effect on the catalytic activity and that N-terminal truncations 
could be more amenable to recombinant expression and yet remain suitable 
for studying the enzymatic function of OGT. Accordingly, I made serial 
truncations sequentially removing TPR repeats, with construct boundaries 
derived from the structural information, and expression constructs were 
generated in pGEX6p1 vector for bacterial expression with a cleavable GST 
tag.  
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Figure 2.2: the stability of each TPR truncations (A) and primary purification of Δ9 hOGT (B).!
A. Equal amount of hOGT proteins bound to the glutathione beads were taken and incubated at 
room temperature for 24 hrs without protease inhibitor. The products were analyzed by Coomassie 
blue protein stain. B. Δ9 hOGT was expressed in ArcticExpress E coli. GST-tagged protein was 
purified on glutathione sepharose beads (Bound) and the tag was cleaved off by Prescission 
protease, releasing D9 hOGT to the flow through (FT) and leaving the protease on the beads.      !
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After comparing the amount of soluble protein obtained from expression in 
different E. coli strains, a commercial ArcticExpress strain, which is 
engineered to co-express a chaperone protein to help with protein folding at 
low temperatures, was selected as the expression system (data not shown). 
Although a chaperone protein was co-purified in the first stage of purification 
(Fig. 2.1B), this was efficiently removed by anion exchange chromatography 
(Fig. 2.3A, B). Further purification by size exclusion chromatography was 
judged unnecessary (Fig. 2.3C, D). All 13 TPR truncations could be produced 
in this way, but notably, the deletion of 9	    TPR repeats (∆9-hOGT, amino 
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Figure 2.3: Further purification of Δ9 hOGT by anion exchange chromatography 
and size exclusion chromatography. -
A, B: Affinity purified Δ9-hOGT (B, input) was loaded onto HiTrap Q FF inion exchange 
column. Protein was eluted with a 0-1 M NaCl gradient (Green line). Purity of each 
fractions were checked by Coomassie blue staining before pooling together. C, D: Δ9-
hOGT was further purified by size exclusion chromatography on a Superdex 75 column. 
Purity of the fractions was checked by Coomassie blue staining.   -
 -
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acids (314-end) gave the highest expression levels and was shown to be 
more stable than the other truncations (Fig. 2.2). From a 12 L culture around 
15 mg of pure ∆9-hOGT protein was produced. ∆9-hOGT protein was later 
used in crystallisations trials described in Chapter II. 
 
2.3.2. hOGT TPR on substrate specificity  
As a first step in investigating the roles of individual hOGT TPR motifs in 
recognition of specific substrates, in vitro activity of hOGT with TPR 
truncations was determined on total HEK293 cell lysate. Mammalian cells 
grown in culture possess a high level of protein O-GlcNAcylation. To remove 
this background O-GlcNAcylation and thereby improve the signal margin, the 
cell lysate was treated with an active bacterial O-GlcNAcase, CpOGA, to 
remove all O-GlcNAc prior to in vitro O-GlcNAcylation with OGT TPR 
truncation mutants (Fig. 2.4). In order to minimise any interference of 
CpOGA (nM) 10 3 1 10 3 1 10 3 1 0 
15 min 30 min 60 min 
170KDa- 
130KDa- 
95KDa- 
72KDa- 
55KDa- 
O-GlcNAc 
(CTD) 
Loading  
control 
Figure 2.4: removal of O-GlcNAc modification on HEK293 
lysate using CpOGA 
50 μg of crude lysate from HEK293 cells was treated with 
indicated amount of CpOGA for different period of time. O-
GlcNAcylation was detected by Western blotting using CTD 
antibody.  
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Figure 2.5: in vitro activity of hOGT with TPR truncations on 293 cell lysate !
A. Schematic representation of the TPR truncations."
B. HEK293 cell lysate has been treated with CpOGA to remove the O-GlcNAcylation. 
The cell lysate was subjected to recombinant hOGT with C-terminal TPR truncations. 
Reaction was performed in the presence of UDP-GlcNAc for 30 mins and stopped by 
boiling in sample buffer before SDS-PAGE and Western blotting. Total O-GlcNAc signal 
was detected with RL2 antibody. The presence of recombinant OGT was detected by 
anti OGT antibody. Loading was confirmed by Ponceau Red.   "
"
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endogenous hOGT and hOGA, the reaction was performed in the presence of 
1 μM of the O-GlcNAcase inhibitor GlcNAcstatin C (Ki=4.6 nM, (Dorfmueller et 
al, 2009)), using high concentrations (up to 0.5 μM) of recombinant hOGT, 
which allowed for short reaction times (30 mins). Total O-GlcNAc levels did 
not gradually decrease with progressive removal of TPRs, rather, there 
appeared to be a step-wise loss of activity (Fig. 2.5): hOGT lacking up to 5 
TPRs in hOGT (∆2-∆5 hOGT) was able to produce high levels of O-GlcNAc 
on lysate in vitro. A dramatic decrease in total O-GlcNAcylation was observed 
when TPR 6 was removed. Similarly low levels of O-GlcNAcylation were 
obtained for all truncations up to ∆11-hOGT. The removal of TPR 12 and TPR 
13 completely abolished OGT activity on total cell lysate. Notably, unlike the 
full-length enzyme, certain truncation mutants were prone to 
autoglycosylation. Auto-O-GlcNAcylation was observed on hOGT with TPR 
10, TPR 11 and TPR 12 deletions (∆10-, ∆11-, ∆12-hOGT), but not on TPR 13 
deletion (∆13-hOGT). This highlights the preservation of enzymatic activity of 
Table 2.1: Summary of protein substrates tested for in vitro O-GlcNAcylation with TPR 
truncation mutants 
Name! Length! Construct! Flexibility! O-GlcNAc site(s)! References!
TAB1! 504aa! 7-402! Yes! S395! Pathak et al., 2011!
CK2α! 391aa! 1-391! Yes! S347! Tarrant et al.,  2012 !
FOXO1! 665aa! 2-655! Yes! T317, T318 (T648, S654 predicted)! Housley et al., 2008!
CREB! 341aa! 1-283! No! S40, T228, S260! Rexach et al., 2012 !
GSK3b! 420aa! 2-420! No! N-terminus! Trinidad et al., 2012 !
YES1! 543aa! 1-543! Yes! N-terminus!
Trinidad et al., 
2012 !
!
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∆10-, ∆11-, and ∆12-hOGT, which had showed little activity on cell lysates.	   
 
Further in-depth investigations of the effect of hOGT TPR truncations were 
performed on several bona fide O-GlcNAc target proteins. These included the 
transcription factors FOXO1 and CREB, a kinase GSK3β, the innate immunity 
signalling protein TAB1, casein kinase 2 subunit α (CK2α), and a Src family 
kinase (SFK) Yes1 (Housley et al, 2008; Lubas & Hanover, 2000; Pathak et 
al, 2012; Rexach et al, 2012). Recombinant proteins or relevant domains, 
CREB (1-283), FOXO1 (2-655), GSK3β (2-420), TAB1 (7-402), CK2 (1-391) 
and Yes1 (1-543), were expressed in E. coli or insect cells and provided by 
DSTT (the Division of Signal Transduction and Therapy of the University of 
Dundee). In vitro activities of hOGT with TPR truncations were determined on 
these proteins (Fig. 2.6). The data showed that TPR truncations in OGT has a 
negligible effect on the O-GlcNAcylation of TAB1 and CK2, as well as full-
length FOXO1 (upper band at around 65 kDa); all TPR truncations of hOGT 
are capable of modifying these proteins, except for the TPR 13 deletion, 
which did not show any activity on these substrates. The recombinant FOXO1 
protein showed significant levels of degradation products, which also appear 
to be substrates for hOGT, appearing on Western blots as multiple bands 
below the full-length protein. Compared to the full-length protein, the levels of 
modification on these lower bands appear to be more sensitive to truncations 
of the enzyme. OGT activity remains at an evenly high level when 6 TPRs are 
removed, is reduced when 7 TPRs are removed, and completely abolished 
upon deletion of more than 7 TPRs. A very similar pattern is seen for CREB, 
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Figure 2.6: Affects of TPR truncations in hOGT on selected OGT substrate 
proteins!
Recombinately expressed OGT substrate proteins were subjected to in vitro O-
GlcNAcylation with TPR truncation mutants of hOGT. Reaction was stopped by boiling in 
sample buffer before SDS-PAGE and Western blotting. O-GlcNAcylation on the 
substrate proteins was detected by anti O-GlcNAc RL2 antibody. It is noticeable that 
CREB and FOXO1 are degraded and generate protein fragments. Δ10-, Δ11- and Δ12-
hOGT O-GlcNAcylated, which was not detectable in other truncation proteins!
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which is a substrate for full-length OGT and truncations up to TPR6, and to a 
limited degree up to TPR7. The boundary is even more pronounced for 
GSK3β and Yes1; removing more than 6 TPRs results in loss of OGT activity 
on GSK3β and Yes1 (Fig. 2.6). As summarised in Table 2.1, O-GlcNAcylation 
sites on TAB1 and CK2α are Ser395 and Ser347, both of which are located in 
a flexible region of the respective protein (Pathak et al, 2012; Tarrant et al, 
2012). O-GlcNAcylation on FOXO1 has been reported at Thr317 and Thr318 
(Housley et al, 2008) while two additional sites, Thr648 and Ser654, at the C-
terminus have also been suggested. Thr317 and Thr318 are predicted in the 
structured region while the final two sites, Thr648 and Ser654, are close to the 
predicted disordered C-teminus. CREB is O-GlcNAc modified at Ser40, 
Thr228 and Ser260, all of which are likely, according to secondary structure 
predictions, to be located in structured regions of the protein (Rexach et al, 
2012). Modification sites on GSK3β and Yes1 have not been reported, 
however, mass spectrometry studies have suggested that O-GlcNAc 
modifications are located close to the N-termini of both proteins.  
 
2.4. Discussion (Part1): 
2.4.1. Dimerization and substrate recognition 
In ncOGT, approximately half of the protein forms the TPR domain, which is 
shorter in mOGT and sOGT (Shafi et al, 2000). It has been shown that the 
TPR domain contributes to substrate specificity (Chen et al, 2013; Iyer & Hart, 
2003; Lubas & Hanover, 2000; Tseng et al, 2001; Yang et al, 2002; Zhang et 
al, 2012a). Structural analysis of the TPRs from hOGT showed a superhelical 
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structure that protrudes away from the catalytic site (Jinek et al, 2004; 
Lazarus et al, 2011). This architecture creates a large surface area and a 
large groove running along the inside of the helix, possibly aiding in the 
interaction with substrate proteins. The extensive surface of the TPR domain 
suggests that the protein-protein interaction may occur at specific positions on 
the TPR motifs, which would create a large diversity for OGT substrate 
recognition. One would expect that systematic removal of individual TPR 
repeats from the N-terminus might produce a gradual effect in reducing the 
number proteins that are recognised in a pool of substrates. However, this 
gradual effect was not observed in vitro when the series of truncated hOGT 
constructs was tested on total cell lysate. Instead, the activity of OGT was 
decreased in three major steps along with the TPR removals.  
 
In the series of TPR truncations of OGT, deletions of the first TPRs from N-
terminus up to TPR 5 retained high activity on cell lysate proteins 
indistinguishable from the full-length enzyme, but the activity is dramatically 
decreased after TPR 6 is removed, which suggests its importance in OGT 
activity on substrate proteins. It has been shown that OGT forms a 
homodimer in cells and a crystal structure of the TPR domain of hOGT 
suggests that several residues in TPRs 6 and 7, especially the hydrophobic 
residues (W198, L199, I201, I230), lie at the dimer interface and are 
indispensable for dimerization (Jinek et al, 2004); mutations of these residues 
disrupt the dimerization and lead to OGT activity loss by 50% on nuclear pore 
protein p62. In our experiment, deletion of TPR 6 could lead to disruption of 
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the OGT homodimer and decrease OGT activity as in the previous report 
(Jinek et al, 2004).  
 
The next significant decrease in O-GlcNAc signal was observed upon the 
deletions of TPRs 12 and 13, which almost abolished the O-GlcNAcylation of 
lysate proteins. Auto-O-GlcNAcylation on ∆12-hOGT indicates its enzymatic 
activity, unlike OGT with TPR13 truncation, for which no evidence of 
enzymatic activity was observed. However, it is not clear whether this auto-O-
GlcNAcylation occur in a cis- or trans-. One way to find it out is to perform an 
in vitro assay with inactive tagged ∆12-hOGT and detect for O-GlcNAc 
modification. The position of TPRs 12 and 13 are shown in the crystal 
structure of the hOGT catalytic domain (Fig. 1.15). TPR 13 in particular is 
closely associated with the glycosyltransferase domain (Lazarus et al, 2011). 
From the structure, both TPRs 12 and 13 do not participate directly in forming 
the substrate-binding groove, but create the start of a channel on the concave 
surface of the TPR super-helix. The presence of substrate peptides in hOGT 
crystal structures defines the peptide binding site. Interestingly, the C-
terminus of the peptides were pointed towards the channel created by the 
TPRs, however were not long enough to provide direct evidence for such 
interactions. A slight overall rotation of the TPR domain with respect to the 
catalytic domain (6 Å) has been observed when a peptide substrate was 
bound, creating a more ‘open’ conformation of the groove (Lazarus et al, 
2011). The opening of the TPR groove may allow extended polypeptides to 
bind and interact with highly conserved surface residues. Deletion of TPRs 12 
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and 13 could affect the interactions with the peptide and would be particularly 
likely to affect the activity on larger polypeptides, as observed in our 
experiment. TPR 13 especially is in close contact with the catalytic domain 
and might be required for the structural integrity of the enzyme; deletion 
appears completely inactive the enzyme, as was observed for all substrates 
tested, including the proteins TAB1, CK2α and FOXO1 (Fig. 2.6).   
 
Giving the fact that three OGT isoforms differ in numbers of TPR present in 
the N-terminus, it has been shown isoform specific substrate recognition on a 
selection of substrate proteins (Lazarus et al., 2006). The activity of sOGT 
was not detected on any of the substrate the authors tested. sOGT contains 
2.5 TPRs, equivalents to removal of 10.5 TPRs. It has been demonstrated 
here that removing of 10 and 11 TPRs from ncOGT abolished substrate 
recognition on many substrates tested, but still retains activity on substrates, 
which adopts flexible conformation at the modification site. This observation is 
in agreement with previous reports by others that sOGT is an active enzyme 
on peptide (Dehennaut et al., 2008, Ma et al., 2013). This isoform specific 
substrate recognition was also tested in vivo with microinjection into Xenopus 
oocytes, where ncOGT was able to accelerate germinal vesicle breakdown 
while sOGT was not (Dehennaut et al. 2008), further suggesting its biological 
relevance.     
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2.4.2. Mechanisms of OGT substrate recognitions 
Further analysis of O-GlcNAcylation on protein substrates by OGT with TPR 
truncations suggests two distinct OGT substrate recognition mechanisms. In 
the experiments, two groups of OGT substrate proteins were selected based 
on the reported or predicted O-GlcNAcylation sites in correlation to their 
positions in the protein structure. O-GlcNAcylation on proteins CREB, GSK3β, 
Yes1 and FOXO1 fragments was dependent on the length of the TPR domain 
(Fig. 2.6). O-GlcNAc signal on the proteins is greatly reduced or abolished 
when TPRs 7, or subsequent repeats are removed. One explanation is that 
TPRs 7 and 8 are involved in substrate interactions. Further molecular 
analysis has shown that the positions of the O-GlcNAc sites on proteins of 
this group, except for Yes1, are likely to be located in the structured regions of 
the proteins. This has also been observed in several other O-GlcNAcylated 
proteins where sites and structures are known, such as Nup62 (Lubas & 
Hanover, 2000), p53 (Yang et al, 2006) and histione 2B (Fujiki et al, 2011). In 
this case, the immediate surroundings of the modification site would have to 
undergo a conformational change to allow the binding in the OGT active site, 
as it has been shown in several crystal structure that the substrate peptides 
adopt extended conformation, and the substrate binding groove is narrow and 
is unlikely to admit a folded protein substrate (Lazarus et al, 2012; Lazarus et 
al, 2011; Schimpl et al, 2012). A possible explanation is that the interaction of 
substrate proteins with the TPR domain induces a conformational change in 
the substrates, which exposes the modification site. Without this induced-fit 
mechanism involving the interactions with the TPR domain, O-GlcNAcylation 
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will not occur. Alternatively, the loss of activity in TPR 7 and 8 truncations may 
also be due to the disruption of OGT dimerization. In the experiment with total 
cell lysate, a similar effect was observed upon deletion of TPRs 6 or 7. This 
apparent shift of the TPR boundary may be the result of different reaction 
conditions; purified protein substrates are present in much higher 
concentrations in the reaction compared to individual proteins in cell lysate 
samples, and the increase in substrate concentration my overcome reduced 
substrate affinity in the in vitro assay.  
 
The second group of OGT substrate proteins, TAB1, FOXO1 and CK2α, 
contain O-GlcNAcylation sites in regions of the proteins that adopt flexible 
conformations, such as the C-terminal tail in CK2 and the interdomain region 
in TAB1. Rearrangement of the O-GlcNAc peptide therefore will not be 
required in preparation for binding to the OGT active site. OGT substrate 
interaction and protein O-GlcNAcylation are independent of the TPR domain 
in this model. This is indeed what we have observed: truncations in the TPR 
domain have no affect on the OGT O-GlcNAcylation of these protein 
substrates. Recognition and binding of such substrates will resemble those of 
a loose peptide, where the sequence immediately surrounding the O-GlcNAc 
modification site, i.e. the sequon, will predominate in OGT substrate 
recognition. The fact that no such sequon has been clearly observed for OGT 
substrate proteins, suggests that sequon recognition is not the complete story 
in OGT substrate interactions and protein O-GlcNAcylation, which is 
consistent with our proposal of two distinct substrate recognitions: one 
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contingent upon, the other independent of participation of the TPR domain of 
OGT.   
 
  
Figure 2.7: Surface representation of ncOGT homodimer model !
Two ncOGT homodimerise (blue and red) at the interface in the TPRs 6 and 7, forming a 
‘clamp’. Green ribbon shows the CK2 peptide in the active site. The model is generated 
by superimposing the structure of TPR dimer (pdb: 1W3B) and hOGT catalytic domain 
(pdb: 3PE4).   !
 !
Active site!
Intervening 
domain !
Catalytic domain!
TPR domain!
Dimerisation 
interface!
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2.5. Result (Part2): 
2.5.1. YES1 is O-GlcNAcylated on Ser26 and Thr37  
Previously, it has been reported that Src family non-receptor tyrosine kinase 
Yes1 is an OGT substrate and exhibits OGT isoform specific O-GlcNAcylation 
(Lazarus et al, 2006). We have identified the modification by mass 
spectrometry. Recombinant Yes1 was treated with ncOGT in vitro and in-gel 
digested with trypsin after SDS-PAGE. Peptides were analysed by liquid 
chromatography-mass spectrometry (LC-MS/MS). A single peptide of 
16YRPENTPEPVSTSVSHYGAEPTTVSPCPSSSAK49 was identified carrying 
multiple O-GlcNAc modifications, which is in agreement with previously 
reported mass spectrometry analysis in mouse synapse samples (Trinidad et 
al, 2012). The data suggest Ser26 and Thr37 as the likeliest modification 
sites. The peptide is located in the N-terminal region of Yes1. Both residues 
and surrounding sequences are not found in other Src family kinases (SFKs), 
in agreement with the fact that Yes1 is the only member of SFKs that 
undergoes O-GlcNAc modification.  It is known that all SFKs adopt a defined 
SH3-SH2-kinase-tail core structure, in addition to a flexible N-terminal region 
comprised of an SH4 domain and a Unique domain. The O-GlcNAc site(s) on 
Yes1 appear to lie in one of the latter domains in the flexible part of the 
protein, similar to the modification sites on TAB1, CK2 and FOXO1. However, 
unlike TAB1 and CK2 (and, to a limited extent, FOXO1), Yes1 exhibits TPR 
dependent O-GlcNAcylation as was also observed for CREB, in which the 
modification sites are more likely to be located in structured regions of the 
protein.  
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2.5.2. Removal of YES1 kinase domain releases the N-terminal region 
and O-GlcNAcylation on YES1 becomes TPR-independent 
To further investigate roles of OGT TPR motifs and their involvement in Yes1 
recognition, I generated C-terminal truncations of Yes1, removing individual 
domains in order to confirm the site of modification and to investigate whether 
additional domains played any part in substrate recognition by OGT. The 
domain structure of full-length Yes1 being SH4-Unique-SH3-SH2-kinase-tail, 
the constructs SH4-Unique-SH3 (4U3, 1-151), in addition to the full length 
Yes1 (FL, 1-520), were expressed in E. coli with GST-tag, which was 
removed during the affinity purification on glutathione column to produce pure 
Yes1 truncation proteins (see Materials and Methods for details). The 
truncated Yes1 protein was in vitro O-GlcNAcylated with the hOGT TPR 
truncation proteins as described previously and O-GlcNAcylation of Yes1 
proteins were determined by Western blotting. As shown previously, it 
appears that Yes1 O-GlcNAcylation is dependent on TPR 6 of OGT, 
suggesting that there is an additional enzyme-substrate interaction distant 
from the modification site. One would expect to see that C-terminal deletion of 
Yes1 would eventually abolish OGT activity on Yes1, presumably by losing 
the protein-protein interaction. However, all three Yes1 truncation proteins 
remain substrate of hOGT with TPR deletions up to TPR 6, as shown 
previously for the full length Yes1. More surprisingly, the hOGT truncations 
with more than 6 TPRs removed, that have been shown to be inactive on full 
length Yes1 protein, become active on Yes1 protein with the C-terminal 
truncation. That is, short hOGT truncation protein is active on Yes1 protein 
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that has been C-terminal deleted. It seems that the C-terminal domains 
prevent Yes1 O-GlcNAcylation by the shorter OGT TPR truncation (TPRs 7-
12) but does not prevent O-GlcNAcylation by OGT with longer TPRs. The 
interaction of the full length OGT, possibly at TPR6, with the full length Yes1 
disrupts this inhibitory effect by the kinase domain and allows O-GlcNAc 
modification at the Unique domain.   
 
2.5.3. The TPR domain of OGT activates YES1 kinase 
It is know that SFKs are under a tight autoinhibition by the SH3-SH2 clamp; 
releasing the clamp through displacement with high affinity ligand binding to 
SH3-SH2 results in activation of the kinase (Boggon & Eck, 2004; Pawson, 
2004). SFKs are activated by upstream receptor kinases or high affinity SH3 
and SH2 ligand proteins through the displacement of their intramolecular 
inhibition, allowing auto phosphorylation on the activation loop to achieve full 
activation. The data above suggest that OGT interacts with Yes1 through its 
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Figure 2.8: Yes1 become an OGT 
substrate irrespective of TPR 
deletions after the removal of 
kinase domain "
Activity of selected hOGT with TPR 
truncations were tested on the C-
terminal truncated Yes1 1-151 in vitro. 
The reactions were stoppted by 
boiling in sample buffer before SDS-
P A G E  a n d  d e t e c t e d  b y 
immunoblotting with anti O-GlcNAc 
RL2  antibody. Loading of the Yes1 
1 -151 p ro te in was shown in 
Coomassie staining. "
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TPR motifs and may induce the release of the N-terminal region for O-
GlcNAcylation. It was interesting to see whether the interaction of OGT with 
Yes1 plays a similar role as other SH3-SH2 ligands in Yes1 activation. It 
appears that TPR 6 is crucial in OGT-Yes1 interactions. To avoid the affect 
that may be produced by OGT catalytic activity, a hOGT construct with only 
the TPRs (16-400) was designed and purified as described in Jinek et al 
(Jinek et al, 2004). In vitro activity of the sf9 insect cell-expressed full length 
Yes1 was determined on the universal tyrosine kinase substrate peptide 
(poly4Glu:Tyr) using a radiometric assay. Optimal enzyme concentration and 
the reaction temperature were determined, and subsequent reactions were 
performed under conditions satisfying the requirements for steady-state 
kinetics (Appendix). In initial time course reactions, the presence of TPRs did 
not show any significant effect on Yes1 kinase activity (Fig. 2.9A). This is 
perhaps not surprising, given that Yes1 protein was expressed in sf9 cells as 
a constitutively active kinase. Physiologically, Yes1 is subject to negative 
regulation by phosphorylation on Y527 in the autoinhibitory tail, its absence 
leads to the accumulation of autophosphorylation on Tyr416 in the activation 
loop. To remove the autophosphorylation on Tyr416, Yes1 kinase was treated 
with GST-tagged lambda phosphatase. After the reaction, lambda 
phosphatase was removed by glutathione sepharose pull-down and 
othovanadate was added to inhibit any remaining phosphatase activity. The 
activity of Yes1 was reduced by 40% after 10 minutes of lambda phosphatase 
treatment. The treatment further resulted in a temporary lag in initial Yes1 
activity, as seen in the time course (Fig. 2.9B). This lag might be caused by 
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the need to regain autophosphorylation. Most interestingly, however, the 
kinase activity of phosphatase-treated Yes1 was increased by 1.7 times in the 
presence of the TPR domain of hOGT.  
 
  
Figure 2.9: Initial activity and autophosphorylation was increased by OGT TPR 
domain!
A: The kinase activity of Yes1 with or without TPR domain was measured using 
radiometric assay with 32P ATP. !
B: Yes1 was treated with GST-tagged λ phosphatase for 30 mins before removed by 
glutathione beads. Subsequently, the kinase activity of Yes1 was measured as for A in 
the presence of 0.1 mM sodium orthovanadate. Each data point was measured in 
triplicate and connected by straight lines. Error bars represent the standard error of the 
mean.!
 !
A: No λ phosphatase treatment" B: λ phosphatase treated"
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2.6. Discussion (Part2): 
2.6.1. OGT activates Yes1 kinase in three ways 
Yes1 belongs to the Src family tyrosine kinases (SFKs). All nine members of 
this family share high sequence identity in the core region comprised of a ‘Src 
Homologous’ 3 (SH3) domain, an SH2 domain followed by a helix linking 
them to the kinase domain and the C-terminal regulatory tail. SH3 and SH2 
domains play central roles in intramolecular regulation of SFKs (Boggon & 
Eck, 2004; Pawson, 2004). High-resolution crystal structures of Src and Hck 
reveal a tight auto-inhibitory mechanism (Sicheri et al, 1997; Xu et al, 1999). 
The interactions of SH3 domain with the PXXP motif in the linker helix and the 
SH2 domain with the phospho-tyrosine on pY527 in the C-terminal tail region 
create a ‘clamp’ that locks the kinase domain in an inactivate conformation. 
This inactive conformation reduces the flexibility of the kinase domain and 
restrains the accessibility to the active site, blocking the autophosphorylation 
of Tyr416 in the activation loop (Sicheri et al, 1997; Xu et al, 1999; Xu et al, 
1997). Recruitment of SFKs to ligand-activated receptors or interactions with 
other high affinity ligands of SH3 or SH2 displace the auto-inhibitory 
interactions and activate SFKs by releasing the SH3-SH2 clamp, which 
subsequently leads to autophosphorylation at the activation loop resulting in 
full activation of the kinase (Boggon & Eck, 2004; Pawson, 2004). This auto-
regulatory mechanism is employed by all SFKs, as well as Tec family kinases 
and Abelson kinase (Abl) (Hantschel et al, 2003). The N-terminal region of 
SFKs, however, is less well conserved. The SH4 domain, the first 16 amino 
acids in the N-terminus, is usually modified by acylation, the covalent 
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attachment of a long fatty acid, which anchors SFKs to the plasma 
membrane, where they are activated by transmembrane receptor proteins to 
trigger downstream signalling cascades (reviewed in (Resh, 1999)). The 
Unique domain, which follows on the SH4, is even less well understood in 
most SFKs, with the exception of Lck. The N-terminus of Lck has been shown 
to associate with the cytoplasmic tails of the T-cell receptors CD4 and CD8 
through a Zn-finger-like structural interaction (Kim et al, 2003). The Cys 
residues involved in Zn2+ binding in Lck are not conserved. The function of the 
Unique domain of Yes1 remains unclear.  
 
O-GlcNAc modification has been found on Yes1 protein, but not on other 
members of SFKs (Lazarus et al, 2006). We have identified the peptide that 
carries the O-GlcNAc modification, with preliminary site-mapping results 
suggesting O-GlcNAc sites at Ser26 and Thr37, which lie within the Unique 
domain of Yes1. The N-terminal region of Yes1 is predicted to adopt a flexible 
conformation. Despite this, in vitro O-GlcNAcylation with TPR truncations of 
OGT clearly display a TPR-dependent manner of substrate recognition, which 
appears to be in contradiction with the model mentioned above. However, we 
were able to demonstrate that the TPRs are no longer required for Yes1 O-
GlcNAcylation when the C-terminal domains are removed (Fig. 2.8), 
suggesting that the kinase domain of Yes1 prevents O-GlcNAcylation when 
OGT lacks its TPR domain. OGT with an intact TPR domain is able to 
overcome the inhibition by releasing the N-terminal region of Yes1, possibly 
through the interaction with the core region consisting of SH3-SH2-kinase-tail. 
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Figure 2.10: Proposed OGT regulation on Yes1 kinase!
Schematic representation of proposed Yes1 kinase activation by OGT. Yes1 is in a ‘closed’ 
inactive conformation by the classic ‘SH3-SH2 clamp’ with SH2 domain interacts with 
phosphotyrosine at the C-terminal ‘tail’ and SH3 domain interacts with PXXP motif. The N-
terminal region with the myristoylation bound to the core region of Yes1. Interaction of Yes1 
with OGT release the ‘SH3-SH2 clamp’, and promote Yes1 to adopt an ‘open’ active 
conformation. The interaction also release the  N-terminal region, which may promote Yes1 
membrane localization. O-GlcNAc modifications have been observed in the N-terminal 
region of Yes1. It is not known how the TPRs interact with the Yes1 kinase. PM is plasma 
membrane. !
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We propose an unusually close association of the N-terminal region in Yes1 
with the core region. The N-terminal region of Yes1 has unique functions; 
SH4-Unique domains are sufficient to inhibit Src-induced changes in cell 
morphology in experiments with Src/Yes1 chimera proteins (Summy et al, 
2003). We have demonstrated that the TPR domain of OGT alone, without the 
glycosyltransferase activity, is sufficient to promote autophosphorylation of 
Yes1 in the absence of auto-inhibitory pY527. This activation of Yes1 kinase 
activity by the TPR motifs might be the direct effect of disrupting the SH3-SH2 
clamp, or brought about indirectly through the release of the N-terminal 
region. Auto-inhibition by the N-terminal region has previously been observed 
in tyrosine kinase Abl, which shares great sequence homology with SFKs in 
the first 510 amino acids. Crystal structures of Abl showed the myristoylation 
buried in a hydrophobic pocket on the kinase domain (Nagar et al, 2003). 
Removing myristoylation in Abl leads to hyper activation of the kinase; this N-
terminal cap (Ncap) has been suggested to be promoting the formation of the 
SH3-SH2 clamp, thus inactivating kinase activity of Abl (Hantschel et al, 
2003).  
 
I hypothesize that OGT may activate Yes1 through three distinct methods 
(Fig. 2.10): Firstly, interactions of OGT with Yes1 may directly activate Yes1 
kinase activity as mentioned above by disrupting the inhibitory conformation 
caused by the SH2-SH3-clamp. Secondly, interaction of OGT with Yes1 may 
dislodge the N-terminal region and exposes the acylation to the plasma 
membrane, therefore promoting Yes1 membrane translocation, where Yes1 
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would be fully activated. Thirdly, O-GlcNAcylation at the N-terminus may 
stabilise Yes1 membrane localisation. All SFKs are myristoylated at Gly-2, 
where a 14-carbon myristoyl group is covalently attached to the alpha-N. This 
myristoylation promotes SFKs plasma membrane localisation in conjunction 
with a palmitoylation, a 16-cabon fatty acid is covalently attached to Cys side 
chain, which also occurs in the N-terminal region. In addition to these 
acylations, the N-terminal region is rich in positively charged residues, which 
interact with the plasma membrane through electrostatic interactions. 
Phosphorylations have been also reported in this region and been proposed 
to affect the electrostatic effects. O-GlcNAcylation may compete with the 
phosphorylation sites and maintain the electrostatic interaction.  
 
2.6.2. Two OGT substrate-binding models: loose peptide and TPR-
induced fit.  
When OGT acts on peptide substrates, the peptide, in the absence of any 
secondary structure, will be in a flexible conformation, which enables it to 
adopt an extended conformation when binding to the active site of OGT. 
Protein substrates where the O-GlcNAc site lies in an extended flexible 
region, such as the C-terminus of CK2α or the interdomain region of TAB1, 
may be expected to adopt a similarly extended binding mode. The 
opportunities for initial contact and binding could be considered very similar 
for both types of substrates. In such cases, any interaction of substrate 
protein with the TPR domain would be accessory rather than necessary.  
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In contrast to this subset of 'easily accessible' substrates, O-GlcNAcylation 
has been observed in ordered regions of protein substrates, within domains 
and on secondary structure elements on the molecular surface. To allow OGT 
to act on these substrates, we suggest that the binding to the TPR domain of 
OGT may introduce conformational changes, which temporarily expose/give 
access to the region bearing the modification site. One example is provided 
here by the study of Yes1 kinase, which is O-GlcNAc modified in its N-
terminal domain. It appears that binding of OGT induces the release of the 
modification site from the core region of Yes1, thereby allowing its O-
GlcNAcylation.  
 
The TPR domain of OGT also mediates the homodimerisation of the enzyme, 
with the dimer interface located primarily on repeats 6 and 7. Our experiments 
investigating the contributions of individual TPR motifs have highlighted a 
particular requirement for TPRs 6 and 7 in TPR dependent protein O-
GlcNAcylation, which may suggest that dimerization of OGT is required for the 
TPR-induced fit model of substrate recognition. A composite model of the 
ncOGT dimer, based on crystal structures of the TPR dimer and of the 
catalytic domain, reveals the proximity of the catalytic domain to the early 
TPRs from the partner molecule (Fig. 2.7).  This raises the possibility of 
intermolecular cooperative effects, which have not hitherto been studied for 
OGT. It would be interesting to obtain the crystal structure of the OGT dimer 
in complex with a substrate protein, to observe this substrate recognition 
mechanism in action.   
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2.7. Material and Methods 
Constructs information  
Primers used to generate the TPR truncations in hOGT are listed in the 
Appendix. 
 
Expression of the TPR truncations and Δ9 construct purification 
hOGT was expressed in ArcticExpress E. coli (Stratagene) by inoculating 1 L of 
LB medium with 5 ml of overnight culture grown in the presence of 50 μg/l 
ampicillin and 20 μg/l gentamycin and allowing it to grow at 37 °C until OD600 
reached 1.0. The culture was cold shocked at 4 °C for 1 h followed by induction 
with 125 μM IPTG and incubation at 12 degrees for 48 h. The culture was 
harvested by centrifugation at 3,000 g for 30 min and the pellet washed with TBS 
buffer (25 mM Tris-Cl pH 7.5, 150 mM NaCl). The pellet was then resuspended 
in lysis buffer (25 mM Tris-Cl pH 8.5, 250 mM NaCl, 1 mM DTT, 1 mM 
benzamidine, 0.2 mM PMSF and 5 μM leupeptin) and lysed using a continuous 
flow cell disruptor (Constant Systems) at 30 kpsi. The lysate was centrifuged at 
40,000 g, the supernatant filtered through 0.2 μm cellulose acetate filters and 
incubated with glutathione sepharose 4B beads (GE Healthcare) for 2 h at 4 °C 
on a rotating platform. The beads were then washed with washing buffer (25 mM 
Tris-Cl pH 8.5, 250 mM NaCl, 1 mM DTT) and incubated with PreScission 
Protease (200 μg protease per ml of beads) at 4 °C for 16 h. The supernatant 
containing the cleaved protein was diluted to 25 mM NaCl in Tris-Cl, pH 8.5 
before IEX on Q sepharose eluting with a linear gradient of 0.025—0.5 M NaCl. 
Fractions selected were pooled and buffer exchanged into 25 mM Tris-Cl pH 7.5, 
CHAPTER	  I	  
	   73	  
150 mM NaCl and 1 mM THP. The proteins were snap-frozen at 1 g/l 
concentration in the same buffer containing 10 % glycerol for future use. 
 
Protein stability 
20 µg of hOGT proteins of different constructs (Δ1-13 hOGT) that bound to the 
glutathione beads in 50% slurry in the buffer containing 25 mM Tris-Cl pH 7.5, 
150 mM NaCl only was incubated at 22 °C for 24 hours. Proteins were boiled in 
the 1x sample buffer (Thermo Scientific, containing 10% glycerol, 1% Lithium 
dodecyl sulphate (LDS), 1% Ficoll-400, 0.2 M triethanolamine-Cl, pH=7.6, 
0.005% phenol red, 0.005% Coomassie G250 and 0.5 mM EDTA sodium). 
Samples was subject to SDS-PAGE and the protein was analysed by Coomassie 
stain (0.1% Coomassie R250, 10% Acetic acid and 20% methanol).  
 
CpOGA stripping  
HEK293 cells were cultured on 10 cm diameter dishes in 10 ml DMEM 
supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/ml penicillin, and 0.1 mg/ml streptomycin. Cells were lysed 36 hours post-
transfection in 0.1 ml of ice-cold lysis buffer (50 mM Tris-HCl pH=7.5, 1 mM 
EGTA, 1 mM EDTA, 1% (w/v) Triton-X (Sigma), 1 mM sodium othovanadate, 50 
mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 mM DTT, 
1 mM benzamidine and 0.1 mM PMSF). The crude lysates were collected by 
centrifugation at 20000 g for 15 min at 4 °C, and the supernatants were collected 
and divided into aliquots, frozen in liquid nitrogen and stored at -20 °C for future 
use. 200 µg of the total lysate in 100 µl of lysis buffer was treated with 0.5 µg of 
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GST-CpOGA for 1 hour at 37 °C (CpOGA was previously expressed in E. coli 
and purified on glutathione 4B beads and elute with glutathione. Buffer exchange 
with concentrator of molecular cut-off of 50 kDa to remove the glutathione and 
protein is stored in 50 mM Tris-Cl, pH=7.5, 150 mM NaCl and 40% glycerol, 
frozen at -80 °C for future use). CpOGA was removed by 20 µl of glutathione 4B 
beads in 50 % slurry for 1 hour at 4 °C; centrifugation collected supernatant, the 
action was performed twice to ensure the removal of CpOGA and to the final 
supernatant added final concentraton of 1 µM of GlcNAcstatin C. The O-GlcNAc 
depleted 293 cell lysate was frozen at -80 °C for future use. 
 
In vitro OGT reaction on lysate 
30 µg of the striped 293 cell lysate was subjected to in vitro O-GlcNAcylation with 
0.5 µM of purified TPR truncation hOGT in 30 µl of reaction in buffer containing 
50 mM Tris-Cl, pH=7.5, 150 mM NaCl, 1 mM DTT, 1 mM benzamidine, 0.2 mM 
PMSF and 5 μM leupeptin and 1 µM GlcNAcstatin C. The reaction was stopped 
after 30 min at 37 °C by boiling in 1x LDS sample buffer. 10 µl of the sample 
(~10 µg of lysate) was subjected to SDS-PAGE and transferred onto PVDF 
membrane, which was blocked by 5% BSA at room temperature for 1 h. O-
GlcNAcylation on the lysate was detected by anti-O-GlcNAc antibody RL2 
overnight at 4 °C. The signal was detected by ECL after amplification with 
secondary HRP conjuganted anti-mouse antibody. OGT was detected by anti-
OGT antibody (DM17) overnight in the same conditions as for O-GlcNAc 
detection. 
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Recombinant protein expression and purification  
GSK3β (2-420) was expressed in insect cell sf9 using baculovirus system. The 
N-terminally His (6) and EE (EFMPME) tagged protein was purified with Nickel 
NTA-agarose and cleaved by TEV protease (ENLYFQG site). Protein was stored 
in 50 mM Tris-Cl, pH=7.5, 150 mM NaCl and 20% glycerol at -80°C for future 
use. Yes1 (1-543) was expressed in sf9 cells and purified as for GSK3β. CK2α 
(1-139), TAB1 (1-401), FOXO1 (2-655) and CREB (1-283) were expressed in E. 
coli. CK2α and TAB1 were purified by glutathione 4B Sepharose; FOXO1 was 
purified with GSH Sepharose and nickel NTA agarose; CREB was purified with 
GSH Sepharose. All proteins were stored at -80 °C for future use. Yes1 
truncations (1-91, 1-151, 1-260) were expressed in E. coli. Cultures with the cell 
density of 1.0 were induced by 100 µM IPTG. Allowed to grow at 18 °C for 24 
hours and lysed with continuous flow cell disruptor. Purification was the same as 
for hOGT. (Expression and purification of GSK3β, Yes1, FOXO1, CREB was 
performed by DSTT, CK2α and TAB1 was by Dr. Marianne Schimpl) 
 
In vitro O-GlcNAcylation on recombinant proteins 
1-2 µg of the recombinant proteins were used in in vitro reactions with 1 µM of 
hOGT TPR truncations proteins in 20 µl reaction containing 1 mM UDP-GlcNAc, 
1 mM DTT, 50 mM Tris-Cl, pH=7.5, 150 mM NaCl for 60-90 minutes at 37 °C. 
The reactions were stopped by boiling in 1x sample buffer. Samples were subject 
to SDS-PAGE and transferred to PVDF membrane and probed by anti-O-GlcNAc 
LR2 antibody overnight at 4 °C. The signal was detected by ECL after 
amplification with secondary HRP conjuganted anti-mouse antibody. OGT was 
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detected by anti-OGT antibody (DM17) overnight in the same conditions as for 
O-GlcNAc detection. 
 
Kinase reaction of Yes1  
Activity of Yes1 was determined on universal tyrosine kinase peptide substrate 
poly(4Glu:Tyr) in radiometric assay. The assays were performed by using 0.2 to 
5 µg of recombinant Yes1 proteins expressed and purified from sf9 cells as 
described above. The reaction was in a final volume of 30 µl containing 20 mM 
Tris-Cl, pH=7.5, 10 mM MgCl2, 1 mM DTT, 0.1 mM [γ-32P] ATP at 0.3 µCi and 1 
mg/ml poly(4Glu:Tyr) peptide. The reaction was started by adding the [γ-32P] ATP 
into the reaction and incubated at 4 or 16 °C for 10 minutes. At each time point, 
reaction was taken and added into 300 µl of 75 mM ice-cold phosphoric acid to 
stop the reaction. The samples were then applied onto 96-wells P81 assay plate 
and the liquid was decanted by vacuum. The P81 was washed 10x with 300 µl of 
75 mM ice-cold phosphoric acid and air dried. Radioactivity was measured with 
plate reader (PerkinElmer, MicroBeta®).  
 
75 µg of Yes1 was treated with 25 µg of GST-tagged lambda phosphatase in the 
buffer containing 100 mM Tris-Cl, pH=7.5, 150 mM NaCl, 10 mM MgCl2 in the 
final volume of 300 µl at 30 °C for 30 minute and the phosphatase was removed 
by adding 50 µl of glutathione 4B Sepherose and incubated for 30 min at 4°C on 
roller. Repeat the last step and collect the supernatant and added final 
concentration of 1 mM of Na orthovanadate. Where indicated, Yes1 was 
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pretreated with a 5-fold molar access of TPR on ice for 1 hour before the kinase 
reaction.  
 
Mass-spectrometry of O-GlcNAcylation on Yes1  
For the site mapping analysis of enzymatically glycosylated Yes1, in vitro 
glycosylation reactions contained 10 mg of recombinantly (sf9) expressed Yes1, 
5 mM UDP-GlcNAc and 0.5 µg OGT in 50 µl of 50 mM Tris-Cl, pH=7.5, 150 mM 
NaCl, 1 mM DTT for 90 min at 37 °C. Protein sample was buffer exchanged into 
50 mM Na bicarbonate and alkylated by final concentration of 10 mM 
iodoaceamide for 30 minutes at dark before trypsinisation with 0.2 ug of trypsin 
at 30 °C overnight in the filter tube. Digested peptides were collected by 
centrifugation at 3,000 rpm with tabletop centrifuge. The sample was evaporated 
to dryness and reconstituted in 0.1 % formic acid, before separation on a 
PepMap C18 column (75 μ m i.d. x 15 cm x 2 μ m) LC-MS/MS(Bruker Daltonics). 
The mass spectrometry method used was based on alternating CID 
measurements. Raw data was processed and used to search against Mascot.    
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3. Chapter II 
 
Catalytic Mechanism Of Human O-GlcNAc 
Transferase (OGT) 
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3.1. Project Overview: 
O-GlcNAc transferase (OGT) is a key enzyme in the O-GlcNAcylation process. 
Many groups have reported the biochemical and biological characterisation of 
OGTs from many organisms (Hart et al, 2007). At the start of this project, two 
groups had independently reported the crystal structures of a bacterial OGT 
ortholog from the plant pathogen Xanthomonas campestris (XcOGT). They 
were the first structures reported from the GT41 family and confirmed that OGT 
adopts the general GT-B fold as predicted from sequence-based classification 
(Clarke et al, 2008; Martinez-Fleites et al, 2008). The information provided by 
the structures allows speculating on the enzymatic actions of OGT utilising 
UDP-GlcNAc to post-translationally modify intracellular proteins. Therefore, 
XcOGT became an excellent working model towards the understanding of 
human OGT (hOGT) at the molecular level. However, several considerations 
must be taken into account. Firstly, although XcOGT shares high sequence 
conservation at the catalytic domain with the metazoan OGTs (36% identity to 
human OGT, Fig 1.5), it lacks the intervening domain within the catalytic domain 
that is present in all metazoan OGTs. Secondly, no protein substrates have 
been reported for XcOGT so far, questioning whether it is truly a bacterial form 
of O-GlcNAc transferase. And finally, the donor substrate UDP-GlcNAc, known 
as the sugar donor for the metazoan OGTs, shows poor affinity for XcOGT at 
15 mM (Dorfmueller et al, 2011). This affinity is similar to that of UDP-
Glucuronic acid, which shares the structural similarities with UDP-GlcNAc. 
XcOGT has been demonstrated to hydrolyse UDP-GlcNAc over a two-day 
period at relatively high concentrations, this however does not fully support that 
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XcOGT is a peptido-O-GlcNAc transferase (Martinez-Fleites et al, 2008). The 
OGT enzyme catalytic mechanism and action of O-GlcNAc transfer therefore 
remained unknown and structural information from active metazoan OGT was 
highly desirable. Only recently, the crystal structure of human OGT in a complex 
with UDP and acceptor peptide has been reported (Lazarus et al, 2011). The 
complex lacked the position of the GlcNAc moiety; therefore the information did 
not conclusively explain the catalytic mechanism of hOGT. 
 
Limitations in small selective pharmacological inhibitors of OGT represent a 
challenge in studying the biological functions of O-GlcNAc modifications. The 
uracil mimic alloxan inhibits OGT by a) occupying the nucleotide binding pocket 
and b) binding to the active site possibly through covalent modification at a 
catalytic site cysteine residue, C917 (Konrad et al, 2002). Because of its 
chemical nature, it is unlikely that inhibition by alloxan is specific to OGT 
(Zachara & Hart, 2004). Strategies with high throughput screens (HTS) of 
fluorescent-based substrate displacement assay have yielded compounds that 
inhibit human OGT in the low µM range in vitro (Gross et al, 2005). Another 
irreversible inhibitor was reported recently (Jiang et al, 2012). The crystal 
structure of the inhibitor-hOGT complex shows that this bicarbamate compound 
binds to the active site of human OGT by covalently targeting conserved active 
site lysine (K842) and cysteine (C917) residues. An alternative strategy is to 
rationally design competitive inhibitors by mimicking the natural substrate. The 
inhibitors bind to the active site but resist glycosyltransfer. Several such UDP-
GlcNAc analogues have been reported, however they are relatively poor 
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inhibitors of hOGT (Dorfmueller et al, 2011). The chemical nature of this class of 
inhibitors may also result in low cell penetration. A thio-derivative GlcNAc (tetra-
acetyl-5SGlcNAc)(Gloster et al, 2011) that replaces the ring oxygen in GlcNAc 
with sulfur is cell permeable as a per-acetylated prodrug and could hijack the 
hexosamine biosynthetic pathway, resulting in intracellular synthesis of the 
hOGT inhibitor UDP-5SGlcNAc (Fig 3.1). However, UDP-5SGlcNAc is also a 
substrate of hOGT as shown by mass spectrometry (Appendix). This focus on 
the substrate based inhibitor design has been unsuccessful partially because of 
insufficient knowledge of the glycosyltransfer mechanism.  
 
This chapter describes the 
characterization and the enzymatic 
properties of hOGT, through the 
structures of ternary product and 
substrate complexes of hOGT with 
sugar donor and synthetic peptide 
analogs. The structures reveal the 
GlcNAc moiety in the active site, which was absent from previous reports 
(Lazarus et al, 2011). The unambiguous electron density for a peptide provide 
information in the peptide binding in addition to the previously reported peptide 
from casein kinase 2 α (CK2α). An unusual conformation of the UDP-GlcNAc 
analog was observed, which brings the non-bridging oxygen from the α-
phosphate in a close proximity to the acceptor serine hydroxyl group. Together 
with stereoisomers of the α-phosphorothioate analog of UDP-GlcNAc and site-
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Figure 3.1: Chemical structure of 
UDP-5SGlcNAc 
(uridine diphospho-5-thio-N-acetyl-
glucosamine). Noted the sulfur atom 
replacing the ring oxygen of GlcNAc 
shown in orange. 
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directed mutagenesis, the data delineate a new catalytic mechanism for 
inverting glycosyl transfer. 
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3.2. The aims of the work presented here were: 
• To provide structural information of the hOGT catalytic domain 
• To elucidate the catalytic mechanism of hOGT glycosyltransfer and 
identify the catalytic base 
• To identify a point mutation that abrogates hOGT activity without losing 
substrate binding 
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3.3. Result and Discussion 
3.3.1. Crystallisation of hOGT 	  
As described above in Chapter 1, a hOGT construct containing the catalytic 
domain and 4.5 TPRs (or delta TPR9, Δ9-hOGT) produced the best expression 
in E. coli and produced stable protein. Therefore, this protein was chosen for 
crystallisation experiments in order to determine the structure of the enzyme by 
X-ray crystallography. After attempts with several commercial crystallisation 
screens, the Δ9-hOGT protein in the presence of a 10-fold molar excess of UDP 
was found to produce microcrystals in multiple conditions, while in about half of 
the conditions produced mild precipitation. Further optimisation could not 
improve the crystal formation and no X-ray diffraction was observed indicating 
that further construct design, such as minimal trimming of the construct might 
be required. At the same time, Suzanne Walker’s laboratory reported a structure 
of hOGT from a construct spanning amino acids 312-1031, similar to Δ9-hOGT 
but without the C-terminal 15 amino acids, which were predicted to be flexible 
and unstructured (Lazarus et al, 2011). To further study the catalytic 
mechanism of hOGT by crystallography, the ‘Walker’ construct has been used 
replacing the existing Δ9-hOGT construct for crystallisation using the expression 
and purification system described above. Crystallisation of the ‘Walker’ hOGT in 
the presence of UDP or UDP-5SGlcNAc could be reproduced. Point mutations 
in the catalytic site were re-cloned in the ‘Walker’ construct to reduce confusion, 
and unless otherwise stated, all the proteins of wild type (wt) and mutants for 
biochemical and biophysical studies are based on the ‘Walker’ construct.     
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The crystallographic study of hOGT reported a trimetric complex containing the 
reaction product UDP as well as a substrate peptide (pdb: 3PE4) (Lazarus et al, 
2011). The position of the sugar moiety was consequently still unknown. 
Lazarus et al. report that they were unable to obtain complex structures with 
UPD-GlcNAc due to hydrolysis of the substrate. Substrate hydrolysis, i.e. the 
transfer onto a water molecule, may be catalyzed by glycosyltransferases in the 
absence of the native acceptor substrate. Attempts at preventing hydrolysis by 
determining the structure of hOGT with the inhibitor UDP-5SGlcNAc also 
resulted in lack of electron density for the GlcNAc moiety. Such absence of 
signal may show that the substrate has undergone hydrolysis, but it may 
likewise indicate disorder of that part of the molecule. In the XcOGT structure, 
complexes with UDP-S-GlcNAc and UDP-C-GlcNAc showed two different 
GlcNAc positions (2XGO and 2JLB). It suggested that the lack of GlcNAc 
density might not be the result of hydrolysis. Instead, the acceptor peptide may 
be required to be in place to position the GlcNAc moiety. 
(All the crystallisation of the ‘Walker’ hOGT and the data processing were 
carried out by Dr Marianne Schimpl). 
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3.3.2. The product complex of human OGT with UDP and an O-GlcNAc 
peptide - Active site residues participate in positioning, but not transfer, 
of GlcNAc 
 
3.3.2.1. Structure of a ternary hOGT product complex defines a conserved 
peptide-binding mode	   
Previous attempts at determining the 
structure of complexes between hOGT 
and its donor substrate UDP-GlcNAc have 
resulted in hydrolysis of the substrate 
(Lazarus et al, 2011). In order to ascertain 
the precise position of GlcNAc in the 
active site and gain insight into OGT 
substrate recognition a synthetic O-
GlcNAcylated peptide (gTAB1tide) (Fig. 3.2) derived from the regulatory O-
GlcNAc site on the innate immunity signaling protein TAB1 was designed and 
synthesized by Dr Vladimir Borodkin to trap the enzyme/glycopeptide product 
complex (Pathak et al, 2012). hOGT in complex with UDP was crystalized, 
which was then soaked with gTAB1tide before data collection. Electron density 
maps at 3.15 Å, improved by 4-fold non-crystallographic averaging, revealed 
unambiguous density for UDP and gTAB1tide. UDP adopts the same 
conformation as observed in the recently reported hOGT-UDP-peptide complex 
(max. atom shift = 1.0 Å), tethered by interactions with nine residues that are all 
conserved in metazoan OGTs (Fig 1.4). The peptide shows ordered density for 
Figure 3.2: Chemical structures of 
TAB1 peptide and its O-GlcNAc and 
amine derivatives at the reported O-
GlcNAc modified serine.    
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the –6 to +4 subsites (Fig. 3.3C), and adopts a backbone conformation in the –3 
to +3 subsites similar to the previously reported complex of hOGT with a CKII-
derived substrate peptide (VPYSSAQ) for gTAB1tide, TPVSSAN for CK2α (Fig 
3.3C). This suggests that hOGT may impose structural and/or sequence 
constraints on the acceptor peptide and that hOGT specificity at the peptide 
sequence level may be worth exploring. 
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A 	   
C 	   
Figure 3.3: Zoom in view of the hOGT catalytic site  
A. hOGT product complex with full length glycopeptide (gTAB1tide) 
ligand(yellow, GlcNAc is in pink) and UDP (cyan) showing unbiased Fo-Fc 
electron density after four-fold averaging (contoured at 2.5 σ).  
B. The enzyme is shown in cartoon representation with side chains shown as 
sticks with grey carbon atoms. Colours for the glycopeptide and UDP are as in A. 
The α and β phosphates of UDP are labelled with Pα and Pβ, respectively. 
Hydrogen bonds are depicted by dashed lines.	  	  
C. Surface representation of the hOGT active site with reaction products 
gTAB1tide and UDP shown as sticks (the peptide, sugar and UDP are shown 
with yellow, pink and turquoise carbon atoms, respectively). The previously 
reported complex with the unmodified CKII peptide and UDP (PDB code 3PE4) 
is shown as sticks with blue and dark green carbon atoms, respectively.   
	  B 	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3.3.2.2. Active site residues participate in positioning, but not transfer, of 
GlcNAc 
In the gTAB1tide-hOGT complex the β-linked sugar, adopting the 4C1 chair  
conformation, projects into a conserved pocket, where it is tethered by T560, 
H920, L653 and G654 (Fig 3.3B). The methyl group of the N-acetyl moiety 
points between the GT-B catalytic core and the TPR repeats, into a pocket 
formed by C917, M501 and L502, explaining why hOGT can tolerate a diverse 
array of UDP-GlcNAc analogs bearing bulky amido substituents, including azido 
derivatives that are widely used with click-chemistry to identify and enrich for O-
GlcNAc proteins (Vocadlo et al, 2003; Wang et al, 2010). The identity of the 
OGT catalytic base that is thought to activate the Ser/Thr in acceptor proteins 
has been the subject of a number of studies that propose either of two 
histidines, H498 or H558, as candidates (Clarke et al, 2008; Lazarus et al, 
2011; Martinez-Fleites et al, 2008). Inspection of the OGT glycopeptide product 
complex described here reveals that both of these histidines are positioned >4.5 
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Figure 3.4: Activity of hOGT point mutants in an in vitro 
O-GlcNAcylation assay of TAB1 protein. O-GlcNAc was 
detected by immunoblotting with a pan-O-GlcNAc antibody 
(RL2). WT, wild type. Experiments were performed in 
duplicate, as shown. 
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Å from the acceptor hydroxyl, and lack interacting residues that would support 
either of them acting as a catalytic base (Fig. 3.3B). His498 has been most 
recently proposed as the catalytic base; mutations to alanine or aspartic acid 
inactivate hOGT. When the His498 was mutated to phenylalanine, the enzyme 
retains activity (Fig. 3.4). Interestingly, a phenylalanine is found in the 
equivalent position of the Xanthomonas campestris putative OGT, indicating the 
histidine likely to have structural function other than serving as the catalytic 
base. H498E mutation also dramatically decreases the binding of UDP-GlcNAc 
but not UDP, suggesting its involvement in orientating the sugar moiety in the 
donor (Appendix 3). Most interestingly, the candidate for the catalytic base, 
H558 as discussed in the previous section (see section 1.2.2), is sandwiched 
between P559 and D554 with the carboxylate of D554 stacking with the H558 
imidazole side chain. The imidazole side chain of H558 accepts a hydrogen 
bond from a protein backbone amide on (deprotonated) Nδ  (Fig. 3.3B), 
implying that the imidazole Nε, facing the acceptor serine, will be protonated at 
neutral pH, which is not compatible with a role as a general base. Mutagenesis 
of H558, however, was not able to demonstrate the regain of enzymatic activity 
while it was replaced with any other amino acids (Fig. 3.5A). Further attempts in 
rescuing the histidine to alanine and glycine mutation by adding imidazole 
aiming to mimic the histidine was also not successful (Fig. 3.5B). His558 to Ala 
or Phe however did not affect the binding of UDP, UDP-GlcNAc and its 
analogues (Appendix 3). On the other hand, as discussed previously, sequence 
and structural comparison with other glycosyltransferases has suggested that 
D554/H558 may form a catalytic dyad; D554N mutation in hOGT did not abolish 
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its activity. The dyad arrangement was not observed in the structure as Asp554 
residue stacks with His558 (Fig 3.3B). These observations revoke the direct 
involvement of D554 in the catalysis and suggest the effects of the H558 
mutation are presumably due to structural reasons. Furthermore, in the latest 
report by Lazarus et al (Lazarus et al, 2012), authors were also able to trap the 
GlcNAc moiety in complex with hOGT and proposed another hOGT catalytic 
mechanism based solely on the structural information: the base catalysis of 
proton extraction was performed by D554 through the Grotthus chain, where 
proton is passed through a hydrogen network of water. Our finding with the 
D554N mutation has therefore disproved this hypothesis. Tyr841 is another 
residue that has been proposed to be the catalytic base (Martinez-Fleites et al, 
Figure 3.5: Attempts at defining the role of His558 in the catalysis. 
A. hOGT His558 has been mutated in an attempt to identify mutations 
at the site that retain the catalytic activity. Proteins were purified and the 
in vitro activity was determined by in vitro assay and immunoblotting.  
B. Attempts to rescue the activity of hOGT H558A/G mutations by 
addition of imidazole to compensate for the missing histidine side chain.  
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2008); hOGT with the Y841F mutation retains catalytic activity. It is likely that 
Tyr841 forms part of a hydrophobic patch providing structural support for 
neighboring residues and positioning of H498 and K842, which is important for 
catalysis as discussed below.  
 
 
3.3.3. A pseudo-Michaelis complex suggests substrate-assisted catalysis. 
(UDP-5SGlcNAc-Pep-OGT complex) 
3.3.3.1. Trapping the Michaelis complex of hOGT 
Surprisingly, it appears that none of the enzyme side chains closest to the 
acceptor serine can act as a catalytic base. To uncover the identity of this 
catalytic base, it is more desirable to trap a complex with intact substrates. Two 
artificial substrate analogues were used to reduce the rate of enzymatic 
turnover in crystallo, namely UDP-5S-GlcNAc, a recently reported hOGT donor 
substrate analog inhibitor (Gloster et al, 2011), and the aminoalanine derivative 
of the TAB1 acceptor peptide 
(aaTAB1tide), where the serine 
hydroxyl is replaced with a primary 
amine (Fig. 3.2). Notably, although 
turnover is reduced, OGT can utilize 
both UDP-5S-GlcNAc (reported 
reduction of Kcat by factor 14 
compared to UDP-GlcNAc, (Gloster 
et al, 2011)) and aaTAB1tide as 
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Fig 3.6: Glycosyl transfer to N-terminally 
biotinylated TAB1tide and aaTAB1tide 
was determined in a scintillation 
proximity assay by D.B. 
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substrates for glycosyl transfer onto the aminoalanine (Fig. 3.6). The observed 
activity with these pseudo-substrates suggests that they possess catalytically 
competent binding modes, similar to the natural substrates and would be 
suitable for the trapping. 
 
3.3.3.2. Structure analysis of hOGT-UDP-5SGlcNAc-peptide pseudo-
Michaelis complex 
hOGT was crystallized in complex with 
UDP-5S-GlcNAc and soaked with 
aaTAB1tide. Synchrotron data were 
collected to 3.3 Å and electron density 
maps (improved by 4-fold non-
crystallographic averaging) re	   vealed 
unambiguous density of a pseudo-
Michaelis complex (Fig. 3.8A). The 
overall conformation of the enzyme is almost unchanged (RMSD on 698 Cα 
atoms = 0.3 Å, max. atomic shift of any active site residue after overall 
superposition = 0.3 Å). The UDP moiety of UDP-5S-GlcNAc adopts a 
conformation similar to that of UDP in the product complex (RMSD = 0.2 Å, 
max. atomic shift = 1.0 Å), whereas the sugar is tilted away from the acceptor 
compared to the product complex (angle of rotation = ~30°), and is tethered by 
H920/L653, G654/T560 on the O3/O4/O6 hydroxyls respectively (Fig. 3.8B). 
His920 to Ser mutation disrupt the binding of UDP-GlcNAc. Strikingly, the 
observed conformation of the donor substrate is remarkably different from 
Figure 3.7: Chemical structure scaffold 
of UDP-GlcNAc and its derivatives.  
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A 
C 
B 
Figure 3.8: The unusual conformation of the sugar nucleotide in the hOGT pseudo-
Michaelis complex suggests substrate-assisted catalysis. 
A. hOGT pseudo-Michaelis complex with full length peptide ligand (yellow, GlcNAc is in 
magenta) and UDP (cyan) showing unbiased Fo-Fc electron density after four-fold 
averaging (2.5 σ). B. hOGT pseudo-Michaelis complex. Close-up view of the active site 
of hOGT (gray carbons) in complex with the donor analog and inhibitor UDP-5S-GlcNAc 
(pink carbons for the sugar, turquoise carbons for the uridine moiety) and the synthetic 
peptide aaTAB1tide (acceptor serine is replaced with an aminoalanine, yellow carbons). 
Hydrogen bonds are depicted by dashed lines. The α and β phosphates of UDP-GlcNAc 
are labeled with Pα and Pβ, C. respectively.Comparison of sugar nucleotide 
conformations from complexes with GT-B family enzymes. The structures of donor 
substrates in complex with active GT-B family enzymes deposited in the PDB database 
are shown superimposed on the sugar ring. The donor substrate from the hOGT complex 
is shown with pink carbons for the sugar and turquoise carbons in the uridine moiety. 
Sugar nucleotide coordinates were obtained from crystal structures of the following 
enzymes and are depicted in increasingly lighter shades of gray: (Continue to Next page) 
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previously reported structures of GT-B donor complexes (Fig. 3.8C). It appears 
that binding in the OGT active site induces a ‘backbent’ UDP-GlcNAc 
conformation, characterized by unusual torsion angles of the pyrophosphate, 
which positions the sugar directly opposite the α-phosphate (Fig. 3.8C). This 
unusual donor conformation brings the α-phosphate pro-RP oxygen to within 2.8 
Å of the aminoalanine amino group mimicking the serine hydroxyl, suggesting 
that they would form a hydrogen bond. Concomitantly, the carbonyl group of the 
GlcNAc N-acetyl group approaches the serine analog to within 2.9 Å. In fact, 
these two substrate moieties approach the serine analog side chain more 
closely than any atom on the OGT enzyme itself. The acceptor appears to be 
positioned for nucleophilic attack with in-line displacement on the sugar 
anomeric carbon (angle nucleophile-anomeric carbon-leaving group = 151°), yet 
the side chains of H498 and H558 remain > 4.5 Å away from the acceptor 
serine as in the product complex. Thus, inspection of this pseudo-Michaelis 
complex leads to the tentative identification of two non-enzymic functional 
groups, residing on the substrate, as candidates for the elusive catalytic base. 
The hypothesis was tested by devising derivatives of the substrate, UDP-
GlcNAc, analogous to the common practice of testing enzymic bases by site-
directed mutagenesis. 
 
 
 
Figure 1.7: Continued… 
inverting enzymes MurG (PDB code 1NLM), UGT71G1 (2ACW), UGT72B1 (2VCE) and VvGT1 
(2C1Z) and retaining enzymes AGT (1Y6F), OtsA (1UQU and 1UQT) and WaaG (2IW1). 
Selected torsion angles of the donor substrates of active glycosyltransferases belonging to the 
GT-B family plotted in a two-dimensional graph. Analyzed by M.S.	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3.3.4. Chemical Probes and Identification of the Catalytic Base  
 
3.3.4.1. N-Acetyl group of GlcNAc contributes to the binding but not 
catalysis 
To investigate the possibility of a mechanism involving substrate-assisted 
catalysis, a number of UDP-GlcNAc derivatives were prepared by Dr Vladimir 
Borodkin (Fig. 3.7). The two moieties considered as possible candidates for the 
catalytic base were the carbonyl oxygen of the N-acetyl group, as well as the 
non-bonding (pro-RP) oxygen of the α-phosphate, due to their proximity to the 
acceptor serine analog in the pseudo-Michaelis complex (Fig. 3.8B). While the 
carbonyl oxygen of the N-acetyl group has been shown to act as the catalytic 
nucleophile in O-GlcNAc hydrolysis (Macauley et al, 2005), it is not likely to act 
as a general base catalyst in O-GlcNAc transfer, as the low pKa  (approx. − 0.5) 
of such a moiety makes it an unlikely proton acceptor. Lately, a computational 
study based on the hOGT-UDP-peptide structure proposed the proton 
extraction performed by the N-acetyl group (Tvaroska et al, 2012), although the 
study was based on the early hOGT structure that lacks the sugar moiety. To 
test the possibility of which as the catalytic base, the previously described N-
Table 3.1: Binding affinity (Kd ± s.d.) of UDP, UDP-sugars and the α-
phosphorothioate analogs of UDP-GlcNAc as determined by SPR with I.N  
(sensograms are shown in the appendix 4).  
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trifluoroacetyl-UDP-GlcNAc derivative (UDP-GlcNAcF3, Fig. 3.7) was prepared 
(Sala et al, 1998), with the aim of affecting the electronegativity of the N-acetyl 
carbonyl moiety. We found that the UDP-GlcNAcF3 compound bound the 
enzyme with a Kd similar to UDP-GlcNAc and proved to be a functional donor 
substrate for hOGT (Table 3.1), which excludes a significant catalytic role of the 
N-acetyl group.  
 
3.3.4.2. Identification of the catalytic base and proposed non-enzymic 
catalytic mechanism 
As expected, both diastereomers were able to form a complex with the enzyme 
with Kd values similar to that of UDP-GlcNAc (Table 3.1) and underwent non-
enzymatic hydrolysis at rates similar to UDP-GlcNAc (Appendix 5). The SP 
diastereomer was found to be a functional donor in an O-GlcNAc transfer 
reaction (Fig. 3.9A). Strikingly, the RP diastereomer, where the sulfur replaces 
Figure 3.9: In vitro O-GlcNAcylation assay using mechanism-inspired UDP-
GlcNAc analogs (A) and Inhibition of hOGT by the donor analog RP-αS-UDP-
GlcNAc (B) 
A. O-GlcNAcylation of TAB1 by hOGT (residues 312–1031) was detected by 
immunoblotting with a site-specific TAB1 O-GlcNAc Ser395–specific antibody. 
Experiments were performed in duplicate, as shown.  
B. Activity of hOGT on biotinylated TAB1tide was determined radiometrically as 
described in the Experimental Procedures. Measurements were performed by Dr David 
Blair in triplicate (error bars represent the s.e.m.) and values were fitted to the standard 
equation for dose-dependent inhibition in GraphPad Prism 5.0.  RP-αS-UDP-GlcNAc (4) 
inhibited hOGT with an IC50 of 25 µM. 
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the oxygen pointing towards the acceptor serine, was not a substrate (Fig. 
3.9A), and indeed inhibited the reaction with an IC50 of 25 μM  (Fig. 3.9B), 
while not affecting binding of the acceptor peptide (Table 3.1). These data 
suggest that the unusual conformation of UDP-GlcNAc positions the α-
phosphate to act as the catalytic base in hOGT catalyzed O-GlcNAc transfer 
(Fig. 3.11), a mechanism not previously reported for other Leloir-type 
glycosyltransferases and apparently unique to OGT. Further evidence supports 
this mechanism. Dr. David Blair has shown that the acidic leg of a pH-activity 
profile of hOGT (Fig. 3.10) exhibits a pKa of 5.5. In the proposed catalytic 
mechanism there is also a need to stabilize the developing negative charge on 
the β-phosphate of the UDP leaving group. Inspection of the substrate/product 
complexes reveals a perfectly shaped oxyanion hole, constructed by three 
elements: hydrogen bonds from the backbone amides of H920, T921 and T922, 
alignment with a α-helical electrostatic dipole and interaction with the 
evolutionarily conserved K842 (Fig. 1.4). Strikingly, the K842M mutation is 
Figure 3.10: pH profile of hOGT. 
Activity of wild-type hOGT on N-terminally biotinylated TAB1tide in 
phosphate buffer with pH 4–12 was measured by scintillation proximity 
assay by Dr David Blair. Data points show the mean ± s.e.m. of three 
observations. 	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catalytically inactive (Fig. 3.4), and no longer binds the UDP product as shown 
by SPR (Table 3.1). With a theoretical pKa of 10.5, deprotonation of this lysine 
may represent the basic leg of the pH-activity profile of hOGT (Fig. 3.10). The 
hOGT pseudo-Michaelis complex reveals that this lysine stabilizes the unusual 
conformation of the β-phosphate that is required for correct positioning of the α-
phosphate opposite the acceptor serine (Fig. 3.8B). Finally, the proposed 
mechanism explains the surprising observation that UDP	   -5S-GlcNAc is a 
potent and specific inhibitor of hOGT, but not of any other human GlcNAc 
transferases (Gloster et al, 2011). The smaller C5-S-C1 bond angle, the longer 
C5-S/S-C1 bonds and the larger van der Waals radius of the sulfur (Fig. 3.8B) 
would all perturb the trajectory of proton transfer from the acceptor serine 
hydroxyl onto the UDP α-phosphate, a process that so far appears to be unique 
to hOGT. 
 
 
  
Figure 3.11: Schematic representation of the proposed catalytic mechanism of 
hOGT, showing substrate-assisted catalysis involving the sugar donor phosphates. 	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3.4. Conclusion: 
OGT is an essential metazoan O-GlcNAc glycosyltransferase that targets 
specific sites on a large number of protein substrates, utilizing UDP-GlcNAc as 
the donor substrate. We report crystal structures of ternary substrate and 
product complexes, providing snapshots of hOGT catalysis. These data show 
that hOGT binds peptide substrates in a defined orientation and with similar 
conformations near the site of O-GlcNAc transfer. Together with synthetic 
probes, these structures define a new mechanism of inverting glycosyl transfer, 
where the catalytic base is not provided by the enzyme, but by the α-phosphate 
on the donor substrate itself. This differs from other Leloir-type GTs, where this 
function is generally performed by a side chain carboxylate or imidazole 
(Lairson et al, 2008). Participation of substrate phosphates in enzymatic 
catalysis is an established concept for farnesyl pyrophosphate synthases, and 
the cumulative evidence of multiple crystal structures of Clostridium spp 
(Hosfield et al, 2004) glucosylating toxins has led to the suggestion of the β-
phosphate of UDP-glucose as the base in these inverting GT-A family enzymes 
(Ziegler et al, 2008). Lately, a similar mechanism has been proposed for the 
GDP-fucose Protein O-fucosyltransferase (POFUT) (Lira-Navarrete et al, 2011), 
an inverting GT-B family enzyme, although a recent study reporting the 
structure of a GT from the same family, POFUT2 proposes an enzyme side 
chain as the catalytic base (Chen et al, 2012). Intriguingly, the substrates for 
POFUT1 are specific serine residues on EGF repeats of the Notch receptor, 
and the clostridial toxins glucosylate Rho GTPases, so like OGT, these 
enzymes act on protein substrates. The involvement of the UDP-GlcNAc α-
phosphate in catalysis may be what enables OGT to act on both Ser and Thr 
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acceptors, as it provides an evolutionary solution to the simultaneous spatial 
constraints imposed by a large peptide acceptor, the necessity to recognize the 
N -acetyl group on the UDP-GlcNAc donor and the need to accommodate the 
additional γ-methyl group on threonines. The mechanistic insights into hOGT 
catalysis are invaluable for the design of drug-like inhibitors to facilitate further 
research into the cell biological role of O-GlcNAc, and the targeting of human 
diseases such as diabetes and cancer. It is noteworthy that as a part of our 
mechanistic investigations, we have now identified a hOGT point mutant, 
K842M, that appears to be unaffected in substrate binding but is catalytically 
inactive and would be useful for cell biological dissection of the role of OGT as 
an enzyme versus a scaffolding function through its TPR repeats. 
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3.5. Material and Methods 
Crystalisation of hOGT 
Crystallisation experiments were performed by Dr. Marianne Schimpl. Protein 
used in crystallisation was stored in 25 mM Tris-Cl, pH=7.5, 150 mM NaCl and 
1 mM THP (instead of 1 mM DTT). Protein was crystallized in complex with 
donor substrate/product, and crystals were soaked with acceptor/product prior 
to freezing. Vapor diffusion crystallization experiments with hanging drops 
containing 1 μl protein (100 μM in a buffer of 10 mM Tris-Cl pH 8.5, 50 mM 
NaCl, 0.5 mM THP, 1 mM UDP or UDP-5S-GlcNAc) and 0.6 μl reservoir 
solution (1.45 M K2HPO4, 10 mM EDTA, 1 % xylitol) gave bar-shaped crystals 
with maximum dimensions of 0.1 × 0.1 × 0.4 mm after 3—4 days at room 
temperature. These were transferred to a drop of reservoir solution containing 2 
mM of the (glyco)peptide (Ac-PVSVPYS(-β-O-GlcNAc)SAQSTS-NH2) for 30 
min, then cryoprotected (1.45 M K2HPO4, 10 mM EDTA, 27 % xylitol) and 
flash-frozen. Data were collected at the European Synchrotron Radiation 
Facility (ESRF) at 100 K and wavelengths of 0.939 Å and 0.873 Å on beamlines 
ID14-4 and ID23-2, respectively. Crystals belonged to space group P321 and 
contained 4 molecules per asymmetric unit. The structure was solved by 
molecular replacement using the A chain of PDB ID 3PE3 as the search model. 
Model building was performed in Coot, and various programs of the CCP4 suite 
were used for structure refinement. Ligand topologies were calculated using 
PRODRG.  
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In vitro Glycosylation of hTAB1 
1 mg/ml of purified hTAB1 (7—402) was incubated with 0.05 mg/ml of purified 
hOGT in 100 mM potassium phosphate pH 7.5 containing 1 mM UDP-GlcNAc 
and 1 mM DTT. The reaction was allowed to proceed for 1.5 h at 37 °C and 
stopped by addition of SDS loading buffer and heating to 95 °C. The samples 
were subjected to SDS-PAGE and transferred to PVDF membrane followed by 
immunological detection of OGT, TAB-1 and OGlcNAc with primary and 
secondary antibodies diluted 1:5,000 in TBS-Tween containing 3 % bovine 
serum albumin. Site-specific antibody against O-GlcNAc-TAB1 S395 was raised 
in rabbit against a keyhole limpet hemocyanin (KLH)-conjugated glycopeptide 
as described by Pathak et al.(Pathak et al, 2012). The anti-TAB1 antibody was 
obtained from the Division of Signal Transduction and Therapy, University of 
Dundee (DSTT). 
 
hOGT activity measurements by scintillation proximity assay 
The experiments were performed with the help from Dr. David Blair. 
Radiometric detection of OGT activity on peptide substrates was achieved 
through scintillation proximity technology (PerkinElmer). Assays were 
conducted in 20 μl format in 384-well polypropylene plates. Reactions contained 
200 nM hOGT (312-1031), 2 μM biotinylated substrate peptides and 500 nM 
UDP-GlcNAc with 0.3 Ci/mmol UDP-[3H]-GlcNAc as a radioactive tracer, 100 
mM potassium phosphate, 1 mM DTT and 0.2 mg/ml BSA. The reaction was 
stopped by addition of 40 μl of 0.75 M phosphoric acid, and transferred to a 
streptavidin-coated FlashPlate®-384 for detection on a TopCount NXT 
microplate luminescence counter.  
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Surface Plasmon Resonance 
The experiment was performed with the help form Dr. Iva Navratilova. SPR 
measurements were collected using a Biacore T100 instrument (GE 
Healthcare). Streptavidin was immobilized on a CM5 sensor chip using 
standard amine coupling method. 10 mM HEPES, 150 mM NaCl, pH 7.4 was 
used as a running buffer for immobilization. hOGT was biotinylated by mixing of 
hOGT with amine-binding biotin (Pierce) in 1:1 molar ratio. The chip surface 
was primed with running buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT 
and 0.05 % Tween 20) and biotinylated hOGT protein was captured on the 
streptavidin surface. All compounds were injected in duplicates with highest 
concentrations from 10–500 μM depending on affinity, followed by a 1:3 dilution 
series. Association was measured for 1 min and dissociation for 2 min. All 
experiments were run at flow rate 30 μl/min and temperature 25 °C. All data 
were referenced for blocked streptavidin surface and blank injections of buffer. 
Srubber 2 (BioLogic Software) was used to process and analyse data. Affinities 
were calculated using 1:1 equilibrium binding fit. 
 
Chemical synthesis of UDP-GlcNAc analogs and peptides 
Experimental procedures have been reported in (Schimpl et al, 2012). 
 
Differential scanning fluorimetry 
5 µM of hOGT proteins was mixed with 1:1000 dilution of Sypro Orange in the 
final volume of 40 µl containing 25 mM Tris-Cl, pH=7.5, 150 mM NaCl. The 
mixture was contained in clear 96-well PCR plate and the fluorescence was 
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measured by thermocycler (BioRad) with raising 1 °C/min from 25 to 95 °C. 
Data analysis was based on (Matulis et al, 2005). 
 
Biolayer interferometry measurements 
The experiments were performed with the help from Dr. David Robinson. 
Peptide binding affinity to hOGT in the presence of donor substrate was 
measured using the OCTET® RED384 system (ForteBio). hOGT was 
biotinylated by mixing with amine-binding biotin (Pierce) in 1:1 molar ratio. 
Biotin-hOGT was immobilised onto Superstreptavidin biosensors followed by 
blocking with 10 μg/ml biocytin. A second set of Superstreptavidin biosensors 
without hOGT coupling was blocked with biocytin, and washed and equilibrated 
in buffer (25 mM Tris-Cl, pH=7.5, 150 mM NaCl, 1 mM DTT) containing 
UDPGlcNAc or RP-αS-UDP-GlcNAc at saturating concentration of 500 mM. The 
biosensors then sampled a 15 dilution series (4 points, 4-fold dilutions) of 
TAB1tide starting from a top concentration of 2.5 mM. Each experiment was run 
using two biosensors and at temperature 25 °C. The data were processed with 
ForteBio Data Analysis v.7.0. Double referencing was used to correct for 
instrument drift and non-specific interactions between TAB1tide and the 
biosensor surface. To obtain the dissociation equilibrium constant (Kd) the 
sensograms were fitted to a global Langmuir 1:1 model using 3 concentrations. 
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4. Chapter III 
 
Structural And Functional Analysis Of 
Drosophila Melanogaster O-GlcNAc 
Transferase 
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4.1. PROJECT OVERVIEW 
As aforementioned in the section 1.5.1, OGT and O-GlcNAcylation have been 
reported to involve in various cellular processes and is essential during 
embryogenesis using genetic models. Many of studies in these animal models 
relied on the complete removal of the ogt gene, which leaves the question 
whether the observed lethality is caused directly by the loss of OGT enzymatic 
activity and consequently the lack of O-GlcNAc modification, or whether it is an 
effect caused by the absence of OGT protein, which is known to participate in 
numerous protein-protein complexes and might have an essential scaffolding 
function. Here, I have used Drosophila melanogaster as a model organism to 
study the importance of O-GlcNAcylation in early embryogenesis and to 
attempt to separate the enzymatic and non-enzymatic functions of OGT. I 
report the crystal structure of Drosophila melanogaster OGT (DmOGT), and 
demonstrate that Drosophila and human OGTs share structural and enzymatic 
similarities. Transgenic flies expressing catalytically inactive DmOGT in the 
ogt/sxc null background were unable to rescue the lethality suggesting the 
enzyme activity, although with almost undetectable amount of O-GlcNAc by 
antibody, is important during embryogenesis and early development in 
Drosophila. 
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4.2. The aims of the work presented here were: 
• To compare OGTs at structural level  
• To identify a peptide substrate enabling DmOGT in vitro activity 
measurements 
• To establish Michaelis-Menten kinetics for DmOGT  
• To generate and verify point mutations that abolish the catalytic activity 
and/or the substrate binding of DmOGT 
• To use these mutant forms of DmOGT in genetic complementation 
experiments with the aim of deconvoluting the enzymatic and non-
enzymatic roles of OGT in vivo 
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4.3. RESULTS AND DISCUSSION 
4.3.1. DmOGT expression and crystallization 
OGT is highly conserved between human and Drosophila (Fig. 1.5 & 4.1), with 
90 % sequence identity in the TPR region and 87% sequence identity in the 
catalytic domain. The most variable domain appears to be the ‘intervening 
domain’, a 135 amino acids insertion between the two Rossmann-like domains 
that constitute the catalytic domain. Sequence identity in the intervening 
domain is only 42 %, and the length differs by 8 amino acids. In order to 
understand to what extent these differences are reflected in the structure and 
function of DmOGT, I crystalized an N-terminally truncated construct starting at 
amino acid 353 in TPR 10 (353-end), which is equivalent to the ∆9-hOGT 
construct. Protein was recombinantly produced in E. coli as for hOGT 
described previously (see Chapter 1). DmOGT expression and purification 
Figure 4.1: Sequence alignment between Drosophila and human OGT at the 
catalytic domain.  
Secondary structures of hOGT (312-1028) and DmOGT (353-end) are shown (sheet 
arrows: β-strand; barrels: α-helices). Identical residues are shaded in blue and residues 
interacting with UDP-GlcNAc are shaded in red. Alignment was generated with Clustal W 
and displayed using Aline.   
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Figure 4.2: Expression and purification of DmOGT. 
A. DmOGT was expressed in ArcticExpress E. coli as for hOGT. GST-tagged protein was affinity-
purified on glutathione sepharose beads (Bound) and the tag was cleaved with Prescission protease, 
releasing DmOGT to the flow-through (FT) and leaving the protease on the beads (Cleaved). B. 
Affinity purified DmOGT (353-end) (C, input) was loaded onto HiTrap Q FF anion exchange column. 
Protein was eluted with a 0-1 M NaCl gradient (Green line). Purity of fractions was verified by 
Coomassie blue staining before pooling (C).  
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proceeded similarly to that of hOGT, with a bacterial chaperone protein co-
eluting in the initial affinity chromatography step (Fig. 4.2). This was later 
removed by anion exchange chromatography, yielding pure DmOGT protein in 
fair yield (approx. 0.5 mg/l culture volume) (Fig. 4.2). In order to crystallize 
DmOGT, a crystallization screen was carried out with ~600 different conditions 
using sitting drop method. Crystals appeared in 4 conditions of the initial 
screen, all of which contain a combination of high molecular weight 
polyethyleneglycol (PEG, above 6000 in mw) and low molecular weight 
alcohols/polyols such as ethylene glycol or glycerol, with pH between 6.5 and 
8.5. This is in marked contrast to hOGT, which has been reported in two 
crystal forms originating from three different buffer conditions containing high 
concentrations of salts (ammonium or lithium sulfate and potassium 
phosphate). Further optimization of the crystallization condition led to needle-
shaped crystals with maximum dimensions of approximately 0.3 x 0.05 mm, 
5 μm 
Figure 4.3: Crystallization of DmOGT (353-end) and X-ray diffraction image. 
A. Needle-shaped crystals grew from a 5 mg/ml protein solution in 12% PEG8000, 
16% glycerol and 0.1 M HEPES 7.5; and appeared after 2 days. B. X-ray diffraction 
images were recorded at Diamond Light Source, UK. Crystals diffract to 3.3 Å. 
A B 
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which belonged to space group H3 and diffracted to >3 Å (Fig. 4.3 & table 4.1). 
X-ray diffraction data were collected at Diamond Light Source, and the 
structure of DmOGT (353-end) was solved by molecular replacement using the 
hOGT structure (pdb: 3PE4) as the search model. Due to the relatively low 
resolution, the absence of any exploitable non-crystallographic symmetry and 
regions of disorder, no attempts were made to fully refine this structure. 
Refinement was terminated after 2 macro cycles.  
 
 
 
4.3.2. Drosophila OGT adopts a canonical GT fold  
DmOGT adopts the canonical OGT fold with the bi-lobular arrangement of two 
Rossmann-like domains of the classic GT-B superfamily glycosyltransferases; 
as well as the additional TPR-like helices (535-566) N-terminal of the catalytic 
domain, which lead into to the TPR domain. As a result, the TPRs are in close 
association with the glycosyltransferase domain and the catalytic site is 
Table&4.1:&Data&collection&and&refinement&statistics&of&DmOGT
Data Collection
Space group H3
Cell dimensions
        a=b, c (Å) 158.2,'76.2
Resolution (Å) 79.1+3.3'(3.39+3.30)
Rmerge 0.079'(0.034)
I/σI 8.9'(2)
Completeness (%) 99.6'(99.8)
Redundancy 2.9'(2.9)
Refinement
Resolution (Å) 30+3.3
No. reflections 10118
Rwork/R free 33.8/41.1
No. atoms 5514
Highest-resolution shell is shown in paretheses 
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aligned with the channel of the TPR superhelix. Superposition of the catalytic 
domain of Drosophila OGT with reported hOGT structure (4AY6) highlights the 
structural similarities (RMSD=0.43 Å for 698 Calphas). The intervening domain, 
an insertion between the two Rossman-like folds of the catalytic domain, faces 
away from the catalytic site and does not appear to be involved in peptide 
substrate recognition. During structure refinement of DmOGT, we noticed that 
the electron density in the intervening domain is less well defined than 
throughout the glycosyltransferase domain, possibly indicating that the 
intervening domain shares less structural similarities to the search model 
hOGT (pdb: 3PE4), or conformational flexibility. This is consistent with the 
lower sequence conservation observed in this region of the protein. The 
functions of the intervening domain are not clear despite the high-resolution 
structure of hOGT (Lazarus et al, 2011). As previously suggested in chapter 1, 
the intervening domain may be involved in substrate protein recognition and 
the structural differences may contribute to differences in substrate recognition 
between hOGT and DmOGT.  
 
Sequence conservation among surface-exposed amino acids is considered a 
sign of functional importance, and can help to identify sites of protein-protein 
interaction. The surface of the DmOGT structure reveals a patch of conserved 
residues mostly concentrated around the catalytic site, but also in the TPR 
domain. The surface-exposed residues involved in UDP-GlcNAc and peptide 
binding are almost identical to hOGT (Fig. 4.4). This conservation is less 
profound in the rest of the catalytic domain. In particular, a group of ten lysine 
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groove and 
active site 
TPR 
motifs 
Glycosyltransferase 
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Intervening 
domain 180° 
Glycosyltransferase 
domain 
Figure 4.4: overall structure of DmOGT and its conservation between human and 
Drosophila. 
DmOGT adopts the canonical OGT fold with the intervening domain (green surface) and 
the TPR repeats (gray surface) closely associated with the glycosyltransferase domain 
(cyan and pink surface) (top left). The surface of DmOGT coloured by sequence 
conservation with hOGT (right panel). Identical residues are shaded in blue, and non-
conserved residues are shown in white. A zoom in view of the catalytic site of DmOGT with 
UDP-5SGlcNAc (green sticks) and TAB1tide (yellow sticks) from superimposed hOGT 
structure (pdb: 4AY6) (bottom left). Red surface indicates residues that interact with UDP-
GlcNAc. 
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residues that form a positively charged pocket in hOGT and have been 
proposed to interact with phosphatidylinositol-(3,4,5)-triphosphate (PIP3), are 
not conserved in DmOGT (Fig. 4.1). No such positively charged pocket is 
observed in the DmOGT structure. Binding of PIP3 to hOGT has been 
proposed to mediate translocation of hOGT to the plasma membrane upon 
insulin stimulation (Yang et al, 2008). However, recent structure-guided 
mutagenesis studies in hOGT could not confirm the binding of PIP3 to these 
lysine residues (Lazarus et al, 2011). The absence of a similar positively 
charged patch on the surface of DmOGT makes it unlikely that PIP3 binding 
could regulate the subcellular localization of OGT in Drosophila.  
  
4.3.3. DmOGT and hOGT possess different peptide substrate sequence 
specificities 
Previously, in vitro activity of DmOGT has been demonstrated using rat 
nuclear pore protein p62 as a substrate (Gambetta et al, 2009; Sinclair et al, 
2009), and no O-GlcNAc modified Drosophila protein has yet been studied in 
detail. However, no substrates are currently known that would allow 
determination of steady state kinetics of wild type and mutant forms of the 
protein. To identify such a substrate, a peptide substrate screen was 
performed on a library of 720 peptides derived from annotated Ser/Thr 
phosphorylation sites on human proteins. The library consisted of synthetic 13-
amino acid peptides with an N-terminal biotin tag, and each peptide contained 
at least one Ser or Thr for post-translational modification. This library was 
screened in 384-well plate format using a scintillation proximity assay 
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developed for high-throughput OGT activity measurements. The highest signal 
was obtained for a peptide derived from human retinoblastoma-like protein 2 
(RBL2)  (KENSPCVTPVSTA). The same sequence has also been observed in 
a similar screen as an optimal hOGT peptide substrate (unpublished data). 
RBL2 is a retinoblastoma family member, which all share high degree of 
structural and functional homology, such as cell cycle, cell differentiation and 
apoptosis (reviewed in (Bellacchio & Paggi, 2013)). RBL2 is conserved in 
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Figure 4.5: Peptide modified by Drosophila and human 
OGT 
Peptide sequences identified from an activity assay against a 
library of synthetic peptides. Listed peptides have been 
shown to be O-GlcNAc modified by hOGT at specific Ser or 
Thr identified with ETD mass spectrometry (performed by D.B 
and O.A). Seven peptides recognized by Drosophila and 
human OGT are shown on top. The peptides are aligned at 
the modified amino acids, which are coloured in red. Green 
lines mark the boundaries of peptide from -5 to +5. Notably, 
the modification sites of substrates for DmOGT are within 5 
amino acids from the C-terminus.   
CHAPTER	  III	  
   117	  
Drosophila with 40% sequence identity, however the peptide sequence and 
modification site is not conserved in the Drosophila protein. The peptide library 
screen also gives insights into the substrate peptide selectivity of DmOGT. A 
similar experiment has previously been performed for hOGT (Dr. Shalini 
Pathak, unpublished work), thus allowing direct comparison of the peptide 
substrate specificity of the two enzymes. The average number of Ser or Thr in 
these 13 amino acid peptides is 2.8 and the site of modification needs to be 
established independently. For the top 40 hits of the hOGT screen, the O-
GlcNAc sites have been unambiguously identified with ETD mass 
spectrometry. For the purpose of this analysis, I assumed that the modification 
sites are the same for DmOGT, although this was not experimentally verified. 
Surprisingly, among the 40 highest-scoring peptides of both screens, only 7 
are common for hOGT and DmOGT, so there is indirect evidence for the sites 
on 7 peptides. In all these DmOGT substrate peptides the modification sites 
were within 5 amino acids of the C-terminus of the peptide (Fig. 4.5). The 
limited number of the peptides does not give conclusive results, but leads to 
speculation of the selectivity of DmOGT on the substrate peptides. Similar to 
hOGT, there appears to be no strict sequence pattern (or ‘sequon’) for O-
GlcNAc modification of proteins. 
 
Interestingly, DmOGT itself is found to carry an O-GlcNAc modification, which 
could be removed by a bacterial O-GlcNAcase, CpOGA (Fig 7A). Mass 
spectrometry analysis located the O-GlcNAc modification (Ser389) 
predominantly in the region of TPR of DmOGT (Fig. 7B). O-GlcNAcylation on 
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the equivalent site has not been reported in hOGT. The position of this O-
GlcNAcylation is on TPR 12 and at the interface between TPRs 12 and 13, 
which is a proposed site of structural flexibility in hOGT (Lazarus et al, 2011). 
In the currently available crystal structures of OGTs (bacterial, Drosophila and 
human), access to the active site is partly occluded by the TPR domain. This 
would either presuppose that O-GlcNAcylation could occur only on flexible 
loops or termini of substrate proteins, or that there is significant movement of 
the TPRs which would allow access of compact substrate proteins to the active 
site. Consequently, a ‘hinge and latch’ mechanism near the catalytic site has 
been proposed, based on a modest positional difference of the TPRs in the 
two crystal structures reported by Lazarus et al. (Lazarus et al, 2011). The 
authors report structures of hOGT in the presence and absence of a peptide 
substrate, and observe a 6 Å shift of TPR 10, and a slight opening of the 
catalytic cleft, in the presence of the peptide. This structural shift of the TPRs is 
due to a hinge-like movement between TPRs 12 and 13. Notably, the two 
structures originated from different crystal forms with unrelated space groups. 
2 ug 0.2 ug Crystal cpOGA 
DmOGT hOGT 
+ - + - 
GlcNAc-OGT 
Total OGT 
DmOGT 
Figure 4.6: O-GlcNAc modification of DmOGT  
O-GlcNAc modification was shown by Western blot on bacteria 
expressed Drosophila (353-end) and human (412-end) OGT with or 
without cpOGA treatment, which removes O-GlcNAc modification (left). 
Right panel shows the O-GlcNAc modified DmOGT in crystals. 5 
crystals were taken and washed 5 times with the mother liquor to 
remove non-crystalised DmOGT and boiled in sample buffer before 
SDS-PAGE and Western blotting. Loading was shown with Coomassie 
blue.  
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Crystal packing can limit the conformational flexibility of multidomain proteins, 
and while the observation does indeed support a certain degree of flexibility on 
the TPRs with respect to the catalytic domain, it is not clear that the movement 
is caused by substrate binding. Other methods better suited to the observation 
of dynamic processes will be required to settle the question of the proposed 
hinge-like movement. Our finding of the O-GlcNAc modification in this position 
could corroborate such a hinge-like mechanism, because a modification of this 
site would invariably disrupt the interaction between TPRs 12 and 13 (Fig. 4.7) 
and lead to a profound rearrangement of the TPR motifs. Although is not 
unusual that post-translational modifications induce structure rearrangement, it 
has not been observed in TPRs. O-GlcNAcylation on TPR 12 could stabilize an 
open conformation of DmOGT, facilitating access to its active site and 
influencing its catalytic activity. O-GlcNAcylation is also observed in protein 
from the DmOGT crystals (Fig. 7A). However, no electron density for the O-
GlcNAc modification was observed in the current crystal structure, possibly 
due to the low resolution. There is little evidence, however, for a major 
rearrangement of the TPRs, although poorer electron density in this region 
suggests a higher degree of flexibility compared to the catalytic domain. It 
would be interesting whether this O-GlcNAc modification influent DmOGT 
selectivity on peptide and protein substrates. 
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4.3.4. The hOGT catalytic machinery is conserved in DmOGT 
DmOGT crystals diffracted to a maximum resolution of 3.3 Å, which enabled us 
to solve the structure. Co-crystallization with UDP, UDP-5SGlcNAc and peptide 
(KENSPCVTPVSTA) did not improve crystallization or the data quality, and no 
clear electron densities for UDP-5SGlcNAc or the peptide were observed. 
However, the catalytic site residues that are found to interact with the UDP-
GlcNAc and the acceptor peptides in hOGT are conserved throughout (Fig. 4, 
bottom left), suggesting a similar catalytic mechanism with the same UDP-
GlcNAc and acceptor peptide binding modes (Fig. 4). In order to explore the 
TPR12 
TPR13 TPR11 
Ser389 
Catalytic Domain 
Figure 4.7: position of Ser389 in TPR12 
Cartoon representation of the DmOGT catalytic domain (with substrates shown in stick 
representation) and TPRs 11, 12 and 13 with Ser389, which as been found to be O-
GlcNAc modified. Ser389 is positioned at the interface between TPRs 12 and 13.  
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mechanistic similarities between the two enzymes, Michaelis-Menten kinetic 
parameters of DmOGT were determined and compared to those of hOGT 
using the same short expression constructs that has been shown to exert 
catalytic activity. The RBL	   2 peptide that has been identified previously from 
the peptide screen was synthesised and used as in vitro substrate for DmOGT, 
to determine Michaelis-Menten kinetics with a radiometric assay. Michaelis 
constant (Km) of UDP-GlcNAc for DmOGT is 17.8 ± 0.7 μM, which is only three 
fold higher than the Km for hOGT at 6.6 ± 0.3 μM (Fig. 5A). Intracellular UDP-
GlcNAc concentration is believed to be a key regulator of OGT enzymatic 
activity and therefore of global O-GlcNAcylation levels. The similar Km values 
of UDP-GlcNAc for Drosophila and human OGT suggests that both proteins 
are subject to regulation by intracellular UDP-GlcNAc levels.  
 
Figure 4.8: Michaelis constant of UDP-GlcNAc and in vitro inhibition of hOGT wt and 
DmOGT wt by UDP-5SGlcNAc!
A. Michaelis-Menten constant (Km) of UDP-GlcNAc on DmOGT wt and hOGT wt were 
determined in a radiometric in vitro assay on RBL2 peptide. Triplicated data points were 
plotted with a Michaelis-Menten kinetic curve fit and Km are shown in table. Error bars 
represent the standard error of the mean B. Half maximal inhibition concentration (IC50) of 
UDP-5SGlcNAc on DmOGT and hOGT were determined using the same assay with UDP-
GlcNAc concentration equal to the Km for each enzyme. Duplicated data points were fitted 
to a three-parameter equation for dose-dependent inhibition and are shown in the table. 
Standard curve and enzyme vs time relationship were shown in the Appendix.  !
A! B!
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The proposed similarities in the catalytic mechanism of human and Drosophila 
OGT were further supported by inhibition with UDP-5SGlcNAc. A novel 
substrate-assisted glycosyltransfer mechanism has been proposed for hOGT 
as discussed in chapter 2. It has been observed that the donor substrate UDP-
GlcNAc adopts an unusual conformation where the non-bridging oxygen of the 
α-phosphate is brought in close proximity to the acceptor Ser or Thr, which 
were activated. This unique catalytic mechanism may lead to the specific 
inhibition of hOGT with a thio-derivative of the donor substrate UDP-5SGlcNAc 
(Gloster et al, 2011), by perturbing the trajectory of proton transfer during the 
deprotonation of the nucleophile acceptor Ser or Thr. Just like the substrate-
assisted catalytic mechanism, this inhibition by UDP-5SGlcNAc seems to be 
unique for OGT. UDP-5SGlcNAc was able to inhibit DmOGT activity with 
inhibition constant (Ki) of 36.2 μM, which is similar to the Ki of hOGT at 13.6 
μM (Fig. 3.5B). This observation further supports the assumption that 
Drosophila OGT adopts the same catalytic mechanism as hOGT, in addition to 
the evidence provided by structural information and Michaelis-Menten kinetics.  
 
4.3.5. Identification of catalytically inactivate DmOGT point mutants 
To investigate and differentiate the non-enzymatic functions of OGT from its 
catalytic activity during embryogenesis and early development, DmOGT active 
site mutations with impaired catalytic activity were designed, based on the 
structure of DmOGT and studies on hOGT (Clarke et al, 2008; Martinez-Fleites 
et al, 2008). The amino acid residues in the active site are highly conserved 
and especially the ones that have been found to interact with the donor 
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substrate UDP-GlcNAc and on the surface of the peptide-binding groove are 
almost identical. It has been found in the structure of hOGT that Asp925 
(DmOGT Asp955) interacts with the uridine and an alanine mutant has been 
shown to abolish hOGT enzymatic activity, primarily by disrupting UDP-GlcNAc 
binding (Clarke et al, 2008; Deplus et al, 2013). H558F (DmOGT H596F) and 
K842M (DmOGT K872M) mutants of hOGT have been described previously to 
be enzymatically inactive but still able to bind to the donor substrate UDP-
GlcNAc with similar affinity to the wild type (Table 4.2). H498A mutation in 
hOGT (DmOGT H537A), on the other hand, has been shown to greatly reduce 
hOGT enzyme activity in vitro and was also selected. All of the aforementioned 
residues were selected to mutate in DmOGT. In vitro O-GlcNAc transferase 
activity was determined using radiometric assay on the previously identified 
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Figure 4.9: Selected mutations in DmOGT 
abolish the enzymatic activity. 
DmOGT (353-end) wt and the mutants were 
expressed in E. coli and purified as described in 
the Material and Methods. The activity of each 
protein was determined on RBL2 peptide in 
vitro with radiometric assay as described in the 
Material and Methods.  
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DmOGT substrate RL2 peptide. While the H537A mutation reduces the 
enzymatic activity of DmOGT to less than 10%, all other three mutations, 
H596F, K872M and D955A have almost no detectable activity. These results 
of DmOGT mutations are in agreement with it of the human enzyme tested 
previously with the same assay set up. Therefore, all of the four mutants were 
selected and used to generate transgenic flies. 
 
4.3.6. DmOGT catalytic activity is essential for Drosophila survival 
To further address this question whether inactive DmOGT could rescue the 
lethality produced by ogt null mutation, we have generated transgenic flies with 
ogt-null background and with the sxc/ogt gene of either the wt (sxc/ogtwt) or 
abovementioned inactive mutants H537A (sxc/ogtH537F), H569F (sxc/ogtH596F) 
Parental genotypes! F1 genotype! Total! Expected ! Rescued! % rescue!
sxc1/CyO; MKRS/TM6 X 
sxc6/Cyo; Tub-GAL4*/
TM6!
sxc1/sxc6; MKRS/Tub-
GAL4! 600! 0! 0! 0!
sxc1/Cyo; ogtwt/TM6 X 
sxc6/TM6; MKRS/TM6! sxc
1/sxc6; ogtwt/MKRS! 600! 0! 0! 0!
sxc1/CyO; ogtwt/ogtwt  X 
sxc6/CyO;Tub-GAL4/
TM6 !
sxc1/sxc6; ogtwt/Tub-
GAL4 (OGT wt)!
!
600! 75! 16! 21%!
sxc1/CyO; ogtH537A/
ogtH537A  X sxc6/
CyO;Tub-GAL4/TM6 !
sxc1/sxc6; ogtH596F/
Tub-GAL4 (OGT 
H537A)!
600! 75! 15! 20%!
sxc1/CyO; ogtH596F/
ogtH596F  X sxc6/
CyO;Tub-GAL4/TM6 !
sxc1/sxc6; ogtH596F/
Tub-GAL4 (OGT 
H596F)!
600! 75! 12! 16%!
sxc1/CyO; ogtK872M/
ogtK872M  X sxc6/
CyO;Tub-GAL4/TM6 !
sxc1/sxc6; ogtK872M/
Tub-GAL4 (OGT 
K872M)!
600! 75! 1! 1%!
sxc1/CyO; ogtD955A/
ogtD955A  X sxc6/
CyO;Tub-GAL4/TM6 !
!
sxc1/sxc6; ogtD955A/
Tub-GAL4 (OGT 
D955A)!
600! 75! 17! 23%!
Table 4.1: Rescue with Drosophila sxc/ogt transgene!
* Tub-GAL4: Mat-α-Tubulin-VP16 – GAL4!
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K872M (sxc/ogtK872M) and D955A (sxc/ogtD955A). The transgenes were 
integrated at the same position on the third chromosome and later crossed 
with transgenic flies carrying sxc1 transgene to generate flies with homozygotic 
genotype of sxc1/Cyo:ogtx/ogtx (x represents wt or the inactive mutants), which 
would double the number of expected offspring carrying ogt transgene. The 
rescue experiment would be performed by ubiquitously driving the sxc/ogt 
transgenes with the tubulin-GAL4 (Mat-α-Tubulin-VP16 – GAL4) driver. The 
maternal tubulin-GAL4 driver was crossed into sxc6 transgenic flies to generate 
sxc6/Cyo:Tub-GAL4/TM6. Female virgins of sxc1/Cyo:ogtx/ogtx were collected 
to cross with male sxc6/Cyo:Tub-GAL4/TM6. Flies were kept in 23 °C incubator 
and 600 embryos were collected and transferred onto fresh fly food and allow 
the embryos to hatch in room temperature. Hatched flies were transferred and 
numbers were taken. According to Mendelian genetics, 75 of the embryos 
should carry the expecting genetic trace, sxc1/sxc6; ogt/Tub-GAL4. The 
transgenic flies with DmOGT wt could support the development to adulthood 
as rescue observed from the previous report (Sinclair et al, 2009). Rescue to 
adulthood by expressing wt DmOGT ubiquitously was 21% (16 adults eclosed) 
as opposed to no recovery in control crosses lacking either the driver or the 
transgene. Interestingly, 15 embryos of total 20% with sxc/ogtH537A transgene, 
12 embryos of total 16% with sxc/ogtH596F transgene, and 17 embryos of total 
23% with sxc/ogtD955A transgene were also recovered in sxc1/sxc6 
transheterozygotic adults background; only one embryo was collected for the 
transgenic flies with K872M mutation  (Table 3.1). To probe the level of 
catalytic activity of DmOGT transgenes in the rescued animals, except K872M 
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mutation, the total O-GlcNAcylation in the flies was determined by 
immunoblotting (Fig. 4.10). We detected minimal levels of O-GlcNAc in the 
offspring rescued by the sxc/ogtH596F and sxc/ogtD955A transgenes. However, 
flies offspring rescued with the sxc/ogtH537A transgene retained total O-
GlcNAcylation levels comparable with those rescued with sxc/ogtwt transgene 
or wt flies as expected since the DmOGT with H537A mutation retains 
reasonable activity in vitro as shown previously. In addition to the rescue of 
transgenic flies with DmOGT H537A and H596F, they were also viable and 
GAPDH!
OGT!
GAPDH!
HA!
GAPDH!
O-GlcNAc 
(RL2)!
100 kDa-!
130 kDa-!
70 kDa-!
55 kDa-!
170 kDa-!
w1
11
8!
W
T!
H5
37
A!
H5
96
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D9
55
A!
Figure 4.10: O-GlcNAcylation in trans-hetrozygotic flies!
Rescued male adult flies collected and lysates were prepared 
from rescued male flies as detailed in Material and Method. Total 
O-GlcNAcylation was assessed by immunoblotting with anti-O-
GlcNAc antibody (RL2). The total DmOGT was probed by anti 
OGT antibody (H300) and the recombinant DmOGT was probed 
by anti-HA antibody. Loading was confirmed by GAPDH. !
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able to produce offspring. However, DmOGT D955A transgenic flies struggled 
to produce offspring that survive to adult. There were not enough transgenic 
flies with K872M mutant to allow crossing. Some noticeable slow development 
was also observed in all of the above transgenic flies (Data not shown). 
 
We suspected that the current in vitro assay set up might not be sensitive 
enough to completely conclude the activity of DmOGT. To further confirm and 
confidently demonstrate the effect of DmOGT catalytic activity with the active 
site mutations, the reactions were performed with exceed amount of enzyme 
(15 times of the original enzyme concentration) for as long as 10 hours of 
reaction time (Figure 3.11). This would allow the signal accumulation of O-
wt 
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Figure 4.11: In vitro activity of DmOGT wt and mutants at high 
enzyme concentration and longer reaction time. 
DmOGT (353-end) wt and the mutants were expressed in E. coli 
and purified as described in the Material and Methods. The activity 
of each protein was determined on RBL2 peptide in vitro with 
radiometric assay in the same conditions as described in the 
Material and Methods, except the reactions were performed with 1.5 
μM DmOGT and reaction for 10 hours. Signal for the wt enzyme 
was calculated from 1 nM enzyme concentration.   "
"
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GlcNAc transfer and increase the signal to noise ratio. The reaction with 
DmOGT wt was performed with 1500 times less enzyme to ensure the reaction 
occurs in the linear phase; later the signal for the wt enzyme was converted 
back to the same enzyme concentration as for the mutants. Interestingly, we 
have detected signal for O-GlcNAc transfer with DmOGT H596F, at less than 
3% of the signal of wt enzyme, which was not detected previously. However, 
the signal for both K872M and D955A remain very low and the mutants were 
more than 11,000 times less active comparing with the wt enzyme. All the 
signal for the O-GlcNAc transfer with DmOGT mutants are less than 5% of the 
total UDP-GlcNAc input and therefore the reactions would be considered to be 
in the linear phase. The results correlate with the rescue experiments that 
active DmOGT H537A and H596F mutants, although with very low enzyme 
activity, were able to rescue the lethality phenotype as the wt enzyme does, 
while the inactive enzyme DmOGT K872M was not, suggesting that the activity 
of DmOGT is important for survival and development of flies. With the current 
detection method, DmOGT D955A mutant has also been shown to be 11,000 
times less active than the wt enzyme, however, the were able to rescue the 
lethality by ogt null mutation, which differs from the outcome produced by 
K872M mutant. Interestingly, these transgenic flies struggle to produce 
offspring that survive till adult stage, indicating the activity of DmOGT and O-
GlcNAc indeed play some roles in survival and development.  
 
sxc/ogt is a PcG gene that functions in homeotic gene repressing; loss function 
mutations of sxc/ogt cause severe homeotic transformation and lethality 
CHAPTER	  III	  
   129	  
(Ingham, 1984; Sinclair et al., 2009 and Gambetta et al., 2009). Recent genetic 
analysis with Chip-ChIP showed O-GlcNAc signal is enriched at the Polycomb 
Response Elements (PREs) in the middle of the promoter region supporting 
OGT functions in gene regulations (Sinclair et al., 2009 and Gambetta et al., 
2009). It has also been shown that in sxc/ogt null fly larvae, a 1.5-2 folds 
reduction of PcG protein polyhomeotic (Ph) PRE localization and downstream 
gene regulation (Gambetta et al, 2009). Genetic studies in C elegans with the 
same approach further suggested that sxc/ogt also involve in insulin signalling 
pathway, energy metabolism and stress through gene regulation (Love et al., 
2010). OGT has been found directly interacts with many transcription factors, 
such as Sin3A, Tet1, Tet2, HCF1, by which OGT might be recruited to 
promoters, many of which have suggested the glycosyltransferase activity of 
OGT is required for these interactions (Chen et al, 2013; Hassig et al, 1997; 
Vella et al, 2013; Williams et al, 2012; Wysocka et al, 2003).  
 
Attempts at rescuing the lethality with the TPR domain only in Arabidopsis 
caused by ablation of both OGT orthologs, Spindly and Secret agent, proved 
unsuccessful. It indicates that OGT without the catalytic domain is not sufficient 
for the embryogenesis (Tseng et al, 2001). On one hand, the catalytic domain 
of OGT has been shown to participate in protein-protein interactions. It has 
been demonstrated that O-GlcNAcylation on neurofilaments is mediated by 
MAPK, which interacts with OGT though the catalytic domain (Cheung & Hart, 
2008). Similarly, the interaction between OGT and Sin3A involves Sp1-
dependent transcription repression, and the catalytic domain of OGT (471-end) 
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lacking the entire TPR domain has been shown to repress transcription (Yang 
et al, 2002). Similar construct or with more TPRs removed has been shown to 
inactivate hOGT (unpublished). It therefore appears that the transcription 
repression occurs through the interaction of Sin3A with the catalytic domain of 
OGT independent of OGT enzymatic activity. On the other hand, it has also 
been shown that inhibition of OGT using an ambiguous OGT inhibitor alloxan 
decreases OGT-HCF1 interaction (Deplus et al., 2013). An elegant approach 
was taken to investigate the interactions with OGT using a catalytically inactive 
enzyme H558A (H568A in the original publication); hOGT H558A has been 
found to destabilize the interaction with Tet1 and also causes protein 
degradation (Shi et al, 2013).  
 
In our rescue experiments in Drosophila, we have generated a structurally 
intact ncOGT that lacks the catalytic activity. We demonstrated that K872M 
mutation of DmOGT could dramatically reduced its enzyme activity by 11,000 
folds in vitro on a peptide substrate and did not rescue the lethality phenotype 
in ogt null transgenic flies. Transgenic flies with another inactive mutant 
D955A, however, could rescue the lethality but struggle to produce healthy 
adult offspring. These findings suggest OGT activity and O-GlcNAcylation are 
required for survival and development of Drosophila. We have also identified 
another mutant H596F, which severely decreased or almost abolished O-
GlcNAcylation in the transgenic flies. However, giving the limitations of in vitro 
assays, it does not completely reflect the activity of the enzyme in a long 
period of time as it has been shown in the longer in vitro reaction as well as in 
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complicated biological systems. Secondly, there might also be a detection limit 
with the antibody used to detect O-GlcNAc levels in flies. Nevertheless, we 
were able to demonstrate a dramatic reduction in the overall O-GlcNAc signal 
in the transgenic flies with active site mutants. 
  
So far, C. elegans is the only model organism reported to survive to adulthood 
with ogt null genotype, this has been used in studies of the involvement of O-
GlcNAcylation in many biological or pathological conditions, especially the 
involvement of O-GlcNAcylation in energy metabolism and diabetes (Forsythe 
et al, 2006; Hanover et al, 2005; Love et al, 2010). However, since sxc 
mutations are lethal, Drosophila with abolished or even reduced O-GlcNAc 
modification would be a good model in addition to C elegans for elucidating the 
details of the physiological functions of OGT. sxc/ogt is a Polycomb group 
gene that has been found to be involved in development of the body axis not 
only in Drosophila, but also in vertebrates (Schwartz & Pirrotta, 2007). It would 
be interesting to investigate the involvement of O-GlcNAcylation during 
development, especially in the nervous system where OGT is highly 
expressed, using these O-GlcNAc null flies.  	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4.4. Material and Methods 
Expression and purification of DmOGT and mutant 
DmOGT (353-end) was expressed in ArcticExpress E. coli and purified as 
described for hOGT (314-end) described in Chapter 1.  
 
Crystallisation 
Protein used in crystallisation was stored in 25 mM Tris-Cl, pH=7.5, 150 mM 
NaCl and 1 mM DTT). Protein was crystallized in complex with UDP-
5SGlcNAc. Vapor diffusion crystallization experiments with sitting drops 
containing 0.5 μl protein (at 5 mg/ml in a buffer of 10 mM Tris-Cl pH=7.5, 50 
mM NaCl, 1 mM DTT, 1 mM UDP-5S-GlcNAc) and 0.5 μl reservoir solution 
(12% PEG8000, 16% glycerol and 0.1 M HEPES pH=7.5) gave needle-shaped 
crystals with approximately 0.3 x 0.05 mm after 2-3 days at 21°C. The crystal 
was flash-frozen without further cryoprotection as the reservoir solution freezes 
clear. Data were collected at the Diamond Light Source, UK, at a wavelength 
of 0.92 Å on beamlines IO4-1, respectively. Crystals belonged to space group 
H3 and contained 1 molecule per asymmetric unit. The structure was solved by 
molecular replacement using the A chain of PDB ID 3PE3 as the search 
model. Initial structure refinement was performed with Refmac5.   
 
Peptide screen 
The screen was performed by Dr. David Blair. A library of 720 biotinylated 
peptide kinase substrates (JPT Peptide Technologies GmbH) consisting of two 
384 polypropylene plates each containing 360 peptides (rows A1 to O24) at 
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concentrations of 0.25 nmols each was solubilised in 62.5 µl of 50 mM Tris (pH 
7.5) to give a final concentration of 4 µM using a PlateMate plus liquid handling 
robot (Thermo Scientific Matrix). A solution of either control (No protein) or 
DmOGT protein (0.5 µM) and UDP-GlcNAc substrate stock (1 µM), consisting 
of 910 nM cold UDP-GlcNAc (Sigma) and 90 nM UDP-[3H]GlcNAc radioactive 
tracer (0.4 Ci/mmol)(American Radiolabeled Chemicals, Inc.) was made up in 
buffer consisting of 50 mM Tris pH=7.5, 2 mM DTT and 0.1 mg/ml BSA. 10 µl 
of 4 µM peptide was added to all 384 polypropylene U bottom plates using a 
PlateMate plus liquid handling robot (Thermo Scientific Matrix). The reaction 
was then initiated by the addition of 10µl of control (No OGT)/ UDP-GlcNAc to 
both QC plate (columns 9-16) and assay plates P13 - P24 to provide low 
controls. All other positions received OGT / UDP-GlcNAc. Plates were 
incubated at room temperature on a micro titre plate shaker (Heidolph) for 240 
minutes.The reaction was stopped by the addition of 40 µl of 100 µM 
phosphoric acid (pH 4) / 750 µM MgCl2 using a Wellmate liquid handling robot 
(Thermo Scientific Matrix). The stopped reactions were incubated for a further 
10 min at room temperature. 56 µl from the QC and screening plates was 
transferred to 384 well streptavidin FlashPlates (PerkinElmer) using a 
PlateMate plus liquid handling robot. Plates were then sealed and incubated 
over night at room temperature before determining scintillation counts using a 
Top Count plate reader (PerkinElmer).  
 
Enzyme kinetics (Km and IC50 and Ki determination) on hOGT and DmOGT 
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The in vitro reactions were performed on RBL2 derived peptide 
(KENSPCVTPVSTA) identified from the peptide screen using radiometric 
assay and the signal was detected by scintillation counter. Assays were 
conducted in the final reaction volume of 20 μl containing 0.05 µM of hOGT 
(314-end) or 0.1 µM DmOGT (353-end), 0.25 mM RBL2 peptides and UDP-
GlcNAc (100 µM, 50 µM, 20 µM, 5 µM, 2 µM, 0.5 µM and 0.05 µM) with 0.3 
Ci/mmol UDP-[3H]-GlcNAc as a radioactive tracer, in the buffer containing 100 
mM Tris-Cl, pH=7.5, 150 mM NaCl and 1 mM DTT. The reaction was stopped 
by addition of 200 μl of 0.75 M ice-cold phosphoric acid containing final 
concentration of 0.5% TFA and 5% ACN. C18 column was used for the binding 
of peptide. C18 column was activated by 200 µl 100% methanol and 
equilibrated twice with 200 µl of equilibration buffer containing 0.5% TFA and 
5% ACN. Samples were passed through the C18 column by centrifugation at 
500 rpm on the table-top centrifuge for 30 seconds and washed 6x with 400 µl 
of equilibration buffer. Peptide bound to the column was eluted by the addition 
of 100 µl 100% methanol followed by evaporation with SpeedVac. 
Radioactivity was detected by the addition of 4 ml scintillation fluid and signal 
was read by scintillation counter.  
 
Half maximal inhibitory concentration (IC50) for the UDP-5SGlcNAc was 
determined with the same experimental set up described for the Km 
determination. The reactions were conducted at the fixed concentration of 
UDP-[3H]GlcNAc (0.3 Ci/mmol) with 5 µM for hOGT and 15 µM for DmOGT, 
both are close to the Km of UDP-GlcNAc for both proteins (6.6 µM for hOGT 
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and 17.8 µM for DmOGT). The inhibitory constant (Ki) of UDP-5SGlcNAc for 
both proteins were calculated by Cheng-Prusoff equation:  
 
 
Enzyme activity of DmOGT wt and mutants 
DmOGT wt and mutants were expressed and purified as described above. 
Assays were conducted in the final reaction volume of 30 μl containing 1 µM 
DmOGT (353-end), 0.25 mM RBL2 peptides and UDP-GlcNAc at 100 µM with 
0.3 Ci/mmol UDP-[3H]-GlcNAc as a radioactive tracer, in the buffer containing 
100 mM Tris-Cl, pH=7.5, 150 mM NaCl and 1 mM DTT, at 37 °C for 90 min on 
a shaker. The reaction was stopped by addition of 200 μl of 0.75 M ice-cold 
phosphoric acid containing final concentration of 0.5% TFA and 5% ACN and 
the peptide were purified with C18 column method described above and 
signals were obtained by scintillation counter.   
 
O-GlcNAcylation on DmOGT by Mass-spectrometry 
The protocol is same to the O-GlcNAc site determination on Yes1 described in 
Chapter 1.  
 
Drosophila genetics 
W1118, sxc1/CyO, sxc6/CyO fly stocks were used 
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UAS::sxc/ogt of wt and the mutants transgenic flies were generated by 
integrating the genes into 86Fb site on the third chromosome and transgenic 
flies were generated by Rainbow Transgenic Flies, Inc, California.    
 
Fly lysis and western blotting 
5 adult flies were anesthetized and frozen on dry ice. The frozen flies were 
homogenized in 100 µl of lysis buffer containing 50 mM Tris-HCl, pH=8.0, 150 
mM NaCl, 1% Triton-X-100, 1 µM GlcNAcstatin C, 5 mM NaF, 2 mM Na 
othovanadate, 1 mM benzamidine, 0.2 mM PMSF, 5 μM leupeptin and 1 mM 
DTT) and left on ice for 60 min for protein extraction. The lysates were 
centrifuged at 16000 g for 10 min and supernatant was collected before 
Bradford assay to determine the protein concentrations. 10 µg of the crude 
lysate was subject to SDS-PAGE and transferred onto nitrocellulose 
membrane before immunoblotting with corresponding antibodies. Signal was 
detected by Odyssey® Li-Cor infrared imaging system.   
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Appendix 
 
 
Primers used to generate TPR truncations on ncOGT 
 
 
 
 
 N-term CTGGGATCC ATGGCGTCTTCCGTGGGCAACG 
d TPR1 CTGGGATCC CCAGACAATACTGGTGTGC 
d TPR2 CTGGGATCC CCCCTTCTGGCAGAAGCTTATTCG 
d TPR3 CTGGGATCC CCTGATTTCATCGATGGTTATATTAACCTGC 
d TPR4 CTGGGATCC CCTGATTTGTACTGTGTTCGC 
d TPR5 CTGGGATCC CCGAACTTTGCAGTAGCTTGGAG 
d TPR6 CTGGGATCC CCAAACTTTCTGGATGCTTATATC 
d TPR7 CTGGGATCC CCAAATCACGCAGTGGTGCACG 
d TPR8 CTGGGATCC CCACATTTCCCTGATGCTTACTGC 
d TPR9 CTGGGATCC CCCACCCATGCAGACTCTCTG 
d TPR10 CTGGGATCC CCAGAGTTTGCTGCTGCCCATTC 
d TPR11 CTGGGATCC CCTACCTTTGCTGATGCCTAC 
d TPR12 CTGGGATCC CCTGCATTTGCAGATGCACATAGC 
d TPR13 CTGGGATCC CCTGATTTTCCTGATGCTTATTGTAAC 
  Reverse CCGCTCGAG TTATGCTGACTCAGTGACTTCAACAGGC 
 
  Reverse TAGAGTCGCGGCCGC TTATGCTGACTCAGTGACTTCAACAGGC 
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Mutagenesis primers for hOGT 
 
hOGT (walker) construct in pGEX 
 
H506F: RLPSVH*PHHS  
f 
gaagaataggttgccttctgtgTTtcctcatcatagtatgctatatc 
r 
gatatagcatactatgatgaggaAAcacagaaggcaacctattcttc 
 
TMT2 H506M: RLPSVH*PHHS  
f 
gagaagaataggttgccttctgtgATGcctcatcatagtatgctatatcc 
r 
ggatatagcatactatgatgaggCATcacagaaggcaacctattcttctc 
 
TMT4 H508N: SVHPH*HSML 
f 
ggttgccttctgtgcatcctAatcatagtatgctatatcctc 
r 
gaggatatagcatactatgatTaggatgcacagaaggcaacc 
 
TMT5 H509F: VHPHH*SMLY  
f 
gttgccttctgtgcatcctcatTTtagtatgctatatcctctttc 
r 
gaaagaggatatagcatactaAAatgaggatgcacagaaggcaac 
 
TMT6 H527W: IAERH*GNLCL 
f 
ggaaggctattgctgagaggTGGggcaacctgtgcttagataag 
r 
cttatctaagcacaggttgccCCAcctctcagcaatagccttcc 
 
TMT7 D564N: VSSD*FGNHP  
f 
gtgtaggatatgtgagttccAactttgggaatcatcctacttc 
r 
gaagtaggatgattcccaaagtTggaactcacatatcctacac 
 
TMT8 H568N: SDFGNH*PTSHL  
f 
gagttccgactttgggaatAatcctacttctcaccttatgc 
r 
gcataaggtgagaagtaggatTattcccaaagtcggaactc 
 
TMT9 T570A: GNHPT*SHLMQ  
f 
gactttgggaatcatcctGcttctcaccttatgcagtc 
r 
gactgcataaggtgagaagCaggatgattcccaaagtTMT10 P666L: MWLGYP*GTSG  
f 
caatgtggctgggataccTtgggacgagtggtgcgc 
r 
gcgcaccactcgtcccaAggtatcccagccacattg 
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TMT11 Q849L: CNFNQ*LYKID  
f 
GatgccatcgtatactgtaactttaatTTgttgtataaaattgacccttctactttg 
r 
caaagtagaagggtcaattttatacaacAAattaaagttacagtatacgatggcatC 
TMT12 Y851F: NFNQLY*KIDPS  
f 
gtatactgtaactttaatcagttgtTtaaaattgacccttctactttgcag 
r 
ctgcaaagtagaagggtcaattttaAacaactgattaaagttacagtatac 
 
TMT13 K852M: FNQLYK*IDPST  
f 
gtatactgtaactttaatcagttgtataTGattgacccttctactttgcagatgtgg 
r 
ccacatctgcaaagtagaagggtcaatCAtatacaactgattaaagttacagtatac 
 
TMT14 V905M: IFSPV*APKEE  
f 
gaaccgtatcattttttcacctAtGgctcctaaagaggaacacgtcagg 
r 
cctgacgtgttcctctttaggagcCaTaggtgaaaaaatgatacggttc 
 
TMT15 K908M: SPVAPK*EEHVR  
f 
cattttttcacctgttgctcctaTGgaggaacacgtcaggagaggccag 
r 
ctggcctctcctgacgtgttcctcCAtaggagcaacaggtgaaaaaatg 
 
 
TMT16 R914M: EEHVRR*GQLADV  
f 
ctaaagaggaacacgtcaggaTGggccagctggctgatgtctg 
r 
cagacatcagccagctggccCAtcctgacgtgttcctctttag 
 
TMT17 C927L: CLDTPLC*NGHTT  
f 
ctgcttggacactccactcCTtaatgggcacaccacaggg 
r 
ccctgtggtgtgcccattaAGgagtggagtgtccaagcag 
 
TMT18 T931A: CNGHT*TGMDVL  
f 
cactctgtaatgggcacGccacagggatggatgtc 
r 
gacatccatccctgtggCgtgcccattacagagtg 
 
TMT19 T932A: CNGHTT*GMDVL  
f 
ctgtaatgggcacaccGcagggatggatgtcctc 
r 
gaggacatccatccctgCggtgtgcccattacag 
 
TMT20 D935N: TTGMD*VLWAG  
f 
cacaccacagggatgAatgtcctctgggcaggg 
r 
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ccctgcccagaggacatTcatccctgtggtgtg 
 
TMT22 H508D: SVHPH*HSML  
f 
ggttgccttctgtgcatcctGatcatagtatgctatatcctc 
r 
gaggatatagcatactatgatCaggatgcacagaaggcaacc 
 
 
 
TMT23 H508E: SVHPH*HSML  
f 
ggttgccttctgtgcatcctGaAcatagtatgctatatcctctttc 
r 
gaaagaggatatagcatactatgTtCaggatgcacagaaggcaacc 
 
TMT24 H508Q: SVHPH*HSML  
f 
ggttgccttctgtgcatcctcaAcatagtatgctatatcctctttc 
r 
gaaagaggatatagcatactatgTtgaggatgcacagaaggcaacc 
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Mutagenesis Primers for Drosophila OGT  
 
H596  A and F 
 
H596A 
 
Aaggaaggcttcgaataggttatctta  
 
 
DmOGT_H596A_fwd 
gctcggacttcgggaatGCtcctacctcgcatttaatgc  
 
DmOGT_H596A_rev 
gcattaaatgcgaggtaggaGCattcccgaagtccgagc 
 
aatctgtgccaggtcttcat 
 
H596F 
 
Aaggaaggcttcgaataggttatctta 
 
DmOGT_H596F_fwd 
gctcggacttcgggaatTTtcctacctcgcatttaatgc 
 
DmOGT_H596F_rev 
gcattaaatgcgaggtaggaAAattcccgaagtccgagc 
 
 
aatctgtgccaggtcttcat 
 
 
 
K872 K872M 
 
Agatgacgctgttgtgtatt 
 
DmOGT_K872M_fwd 
gcaattttaatcagctatacaTGatcgatccacaaaccctcgagtc 
 
DmOGT_K872M_rev 
gactcgagggtttgtggatcgatCAtgtatagctgattaaaattgc 
 
atgggtagaaattttaaaaaatg 
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in vitro kinase reaction with recombinant Yes1 protein. Protein concentration 
vs temperature vs time was to ensure optimised reaction condition and steady 
state kinetics 
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Summary of the activity, protein folding and binding to UDP, UDP-GlcNAc and 
their analogs. 
  
Affinities in uM, ND= not determined due to instrument noise, - = no binding, 
LC=low capture (could be low resolution for binding)  
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Curve fitting for the SPR data of binding of small molecules to hOGT and the 
mutants 
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Data collection and refinement statistics of hOGT  
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Solvolysis of phosphorothioate analogues of UDP-GlcNAc, reaction conditions 
could be found in Schimpl et al., 2012. 
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Top: Standard of UDP-[3H]GlcNAc using scintillation counter.  
Bottom: Time course of DmOGT in vitro reaction.  
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Curve fitting for  
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Differential scanning fluormetry demonstrate the folding of hOGT and its 
mutants  
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